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PART I 
Structural Basis for NHERF1-PDZ2 Dimer Mediated Protein Scaffolding and NHERF2-
LPA2 Complex Assembly 
CHAPTER 1 GENERAL INTRODUCTION 
1.1 Protein Scaffolding 
 The term protein scaffolding can be defined directly as the coming together of two or more  
proteins in which facilitates a stable conformational state and is often required for specific 
biological function6. There are numerous examples of such proteins identified in the literature in 
which play critical roles in many physiological signaling events and are achieved by variety of 
molecular mechanisms. Some key cellular functions of protein scaffolding have been identified to 
include the sorting, recycling, localization and stabilization of cell surface receptors in addition to 
performing critical roles in cell polarity and cell to cell adhesion6-10. Scaffolding proteins often 
exhibit distinct specificity for their binding partners in which lead to particular cellular events. 
However, several instances have also been observed in which certain scaffolding proteins have 
been found to bind to a variety of targets exhibiting specific yet promiscuous binding activity2,6. 
Regardless, these interactions are often stable but dynamic furthering the complexity of the 
mechanistic basis for which these proteins function and regulate various cellular pathways. 
Scaffolding Proteins and Their Functions 
 Scaffolding proteins critical for the formation macromolecular complexes required for 
cellular signaling can be divided into three general categories: arrestins, postsynaptic density 
95/disc large/zona occludens-1 (PDZ) domain-containing proteins, and non-PDZ proteins11. 
Arrestins encompass a small family of proteins important for regulation at G protein coupled 
receptors (GPCRs) with only four members found in mammals. However, even with a lack in 
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recognizable sequence for binding its targets, this family of scaffolding proteins has been shown 
to bind to several hundred GPCRs in order to promote cellular signaling11-14. Arrestins function by 
binding to the cytoplasmic face of GPCRs, preventing its activation or linking the receptor to 
internalization machinery for degradation15. Arrestin structure is highly conserved whereas their 
mechanistic binding to their substrates possess some noticeable differences. In the case of arrestin-
1, it structure is composed of N- and C- terminal β-sheet domains with a series of buried polar 
residues termed the “polar core” in which the N-terminal domain is stabilized by a C-terminal tail 
securing the molecule into an inactive state16,17. However, Arrestin-4 exhibits variable 
conformation in the surfaces of the β-sheets involved in receptor recognition and the loop between 
β-strands 1 and 216,18. This comparison exemplifies aforementioned statement that scaffolding 
proteins are able to achieve distinct specificity for their substrates in order to promote explicit 
signaling events critical to a variety of cellular functions.  
 In addition to the arrestin family, a number of other proteins exist in which contribute to 
macromolecular complexes necessary for specific signaling events. Examples of such would 
include non-PDZ proteins such as A-kinase anchor proteins (AKAPs), Janus kinase (Jak)-2, and 
14-3-3 proteins11. Both AKAP79 and AKAP250 have been shown to interact with the β-2 
adrenergic (β2AR) receptor in which have been shown to promote mitogenic signaling or 
desensitization of β2AR respectively whereas interaction of Jak-2 with AT1R has been shown 
mediate STAT1 complexing with AT1R and promote STAT1 mediated gene transcription 
19,20. 
Additionally, scaffolding of the 14-3-3 proteins such as with the FSH receptor has been shown to 
result in a modest increase in cellular accumulatio of follitropin among other effects11,21. However, 
even with the number of events facilitated by non-PDZ domain proteins, the vast number of 
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implicative actions arbitrated by those containing PDZ domains raise particular interest when it 
comes to the mediation of biological functions. 
PDZ Proteins 
1.2.1 Overview 
 PDZ proteins are a family of proteins involved in the regulation of protein scaffolding and 
cellular signaling in which contain one or more PDZ domains. PDZ is an acronym for the three 
proteins in which were originally identified to possess such a domain which includes post synaptic 
density protein (PSD95), Drosophila disc large tumor suppressor (Dlg1), and zonula occludens-1 
protein (zo-1)22 which have also referred to as  DHR (Discs large homology repeat) domains after 
the highly conserved four-residue GLGF sequence found in these domains23. These domains have 
two primary functions as protein-protein interaction modules including the localization of cellular 
signaling events and regulation of different physiological pathways23. Interaction with their protein 
targets are mediated by recognition of a C-terminal consensus peptide motif most often on the 
cytoplasmic tail of transmembrane receptors and channels23,24. PDZ containing proteins are highly 
abundant in a variety of species with over 900 domains identified in more than 300 proteins in the 
mouse genome25. And due to their prevalence and diversity, it is not difficult to understand how 
this family of proteins could have a significant impact on a wide range of biological functions. 
 1.2.2 PDZ Function 
 As previously stated, PDZ domains are responsible for protein-protein scaffolding which 
lead diverse signaling cascades regulating cellular and physiological function. Due to the vast array 
of proteins containing such domains, there has been continual investigation into a number of these 
proteins and how they function in cellular regulation. Some of the most common and well-studied 
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PDZ proteins include PSD-95, GRIP, HOMER, and the NHERF family. PSD-95 is a synaptic 
protein containing three PDZ domains found to bind and scaffold a variety of membrane proteins 
via its two N-terminal PDZ domains26.  These two domains were first discovered to bind to the C-
termini of Shaker-type K+ subunits and NDMA receptor NR2 subunits resulting in the scaffolding 
of these membrane proteins26,27. Glutamate receptor interacting protein (GRIP) is another post 
synaptic protein containing seven PDZ domains which have been shown to be responsible in 
binding AMPA receptor in a similar fashion as PSD-95 to NDMA28. This interaction has shown 
to cluster AMPA receptors to other proteins at excitatory synapses in brain which is thought to be 
critical in neuroplasticity, learning, and memory storage28,29.  HOMER is also a neuronal protein 
encoded by the HOMER1 gene but with different function to that of either PSD-95 or GRIP per its 
involved in metabotropic glutamate signaling30,31. HOMER contains only one PDZ domain in 
which it binds type 5 metabotropic glutamate receptor (mGluR5) and is expressed at high levels 
during embryonic stages in which suggests it may play an important role in neuronal 
development32. Lastly, the PDZ containing NHERF (Na+/H+ exchanger regulatory factor) family 
have been shown to be involved in wide variety of scaffolding interactions, the implication and 
mechanistic basis of which will be discussed successively. 
1.2.3 The NHERF Protein Family 
 The NHERF protein family consists of four members which have been found to bind to a 
variety of membrane transporters and receptors and have been shown to modulate protein 
expression, mobility, protein-protein interactions and the formation of signaling complexes33. 
Each of the members are differentially expressed in mammalian tissues with NHERF-1 and 
NHERF-2 being the most similar and well-studied. Both NHERF-1 and NHERF-2 contain two 
PDZ domains and have been found to be essential regulators of hormonal signaling by inhibition 
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of NHE3 (Na+/H+ exchanger isoform 3) activity in the renal and gastrointestinal epithelial cells34-
36. NHERF-1 and NHERF-2 have also been shown to associate with the C-terminus of β2AR, ezrin, 
PKA, and CFTR, allowing a variety of agonist signaling with mechanistic specificity33,37. 
Specifically, absence or reduction of NHERF-1 has been shown to display defects in intestinal salt 
absorption and defective intestinal anion secretion33,38,39. Furthermore, NHERF-2 knockout was 
determined to increase CFTR dependent anion secretion but decrease intestinal salt absorption 
however, fluid absorption in in the jejunum of NHERF-2 knockout mice in vivo was shown to 
increase when compared to the wild-type33,40,41.  Both PDZ domains of NHERF-1 have been shown 
to bind to the chemokine G protein coupled receptor CXCR2 in addition to the enzyme PLCβ2 
creating a signal transduction scaffold in which chemokine stimulation of CXCR2 results PLCβ2 
ligand induced calcium signaling2,42,43. This chemokine stimulated PLCβ2 signaling has been 
shown to promote neutrophil migration from the bone marrow to sites of inflammation and 
infiltration into the surrounding tissue exacerbating the inflammatory response in a variety of 
diseases including rheumatoid arthritis, psoriasis, emphysema, and others 2,42,43. The PDZ domains 
of NHERF-2 have been determined to facilitate scaffolding of the cystic fibrosis transmembrane 
conductance regulator (CFTR) with Lysophosphatidic acid receptor 2 (LPA2). This has shown to 
play an inhibitory role on CFTR activity while disruption of this complex has been shown to 
augment CFTR Cl- transport1,44,45. Therefore, due to the influential roles in which the NHERF 
family PDZ domains exhibit in cellular signaling and protein function, elucidation of the structural 
basis in which these interactions occur may provide for greater understanding of their involvement 
in a variety of human disease.   
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CHAPTER 2 CRYSTAL STRUCTURE OF THE NHERF1 PDZ2 DOMAIN IN 
COMPLEX WITH THE CHEMOKINE RECEPTOR CXCR2 REVEALS PROBABLE 
MODES OF PDZ2 DIMERIZATION 
 
*Published in Biochem Biophys Res Commun. 2014 May 30;448(2):169-74. doi: 
10.1016/j.bbrc.2014.04.085. Epub 2014 Apr 24. All authors agreed with including their work in 
this dissertation. 
Abstract 
 The formation of CXCR2–NHERF1–PLCb2 macromolecular complex in neutrophils 
regulates CXCR2 signaling and plays a key role in neutrophil chemotaxis and transepithelial 
neutrophilic migration. However, NHERF1 by itself, with only two PDZ domains, has a limited 
capacity in scaffolding the multiprotein-complex formation. Here we report the crystal structure 
of the NHERF1 PDZ2 domain in complex with the C-terminal CXCR2 sequence. The structure 
reveals that the PDZ2–CXCR2 binding specificity is achieved by numerous hydrogen bonds and 
hydrophobic contacts with the last four CXCR2 residues contributing to specific interactions. The 
structure also reveals two probable modes of PDZ2 dimerization where the two canonical ligand-
binding pockets are well separated and orientated in a unique parallel fashion. This study provides 
not only the structural basis for the PDZ-mediated NHERF1–CXCR2 interaction, but also an 
additional example of how PDZ domains may dimerize, which both could prove valuable in 
understanding NHERF1 complex-scaffolding function in neutrophils. 
Introduction 
 The chemokine receptor CXCR2 is a G-protein coupled receptor that plays important roles 
in regulating neutrophil chemotaxis and directing neutrophils to sites of inflammation46,47. 
Defective regulation of CXCR2 can cause excessive release of neutrophils from bone marrow and 
has been implicated in a variety of inflammatory diseases, including rheumatoid arthritis, psoriasis, 
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inflammatory bowel disease, acute respiratory distress syndrome, septic shock, pulmonary 
emphysema, and chronic obstructive pulmonary disease48. Growing evidence suggests that 
CXCR2 interacts directly or indirectly with other receptors, ion channels, transporters, scaffolding 
proteins, effectors, and cytoskeletal elements to form macromolecular complexes at specialized 
subcellular domains42,49. These dynamic protein–protein interactions regulate CXCR2 signaling 
function as well as its localization and processing within cells50,51. We have shown that CXCR2, 
phospholipase C-b2 (PLCβ2), and Na+/H+ exchanger regulatory factor-1 (NHERF1) form 
macromolecular complexes at the plasma membrane of bone marrow neutrophil, which 
functionally couple chemokine signaling to PLCβ2-mediated signaling cascade42. We also showed 
that disruption of this NHERF1-bridged interaction abolishes CXCR2 signaling and inhibits 
neutrophil chemotaxis and transepithelial neutrophilic migration in vitro42. These findings imply 
that targeting the NHERF1-scaffolded CXCR2–PLCβ2 signaling cascade could provide new 
strategies for therapeutic interventions of CXCR2-related diseases. 
 The ability of NHERF1 to scaffold the formation of a multiprotein complex depends on its 
two PDZ (PSD-95/Discs-large/ZO-1) domains, PDZ1 and PDZ2. In general, PDZ domains 
mediate protein interactions by recognizing the C-terminal sequence of target proteins and binding 
to the targets through a canonically and structurally conserved PDZ peptide-binding pocket23. The 
specificity of the interactions is determined mainly by the residues at positions 0 and _2 of the 
peptides (position 0 referring to the C-terminal residue), whereas other residues do not 
significantly contribute to the interaction23. This has led to the classification of PDZ domains into 
two major specificity classes: type I, (S/T)X(V/I/L) (X denoting any amino acid); type II, 
(F/Y)X(F/V/A)3,52. The PDZ domains of NHERF1 are the type I PDZ domains that have been 
shown to be capable of interacting with many different proteins and robust in scaffolding 
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multiprotein complex formation. In addition to CXCR2 and PLCβ2, the NHERF1 PDZ domains 
are able to interact with a range of other membrane and signaling proteins, such as cystic fibrosis 
transmembrane conductance regulator (CFTR), β2-adrenergic receptor (β2AR), platelet-derived 
growth factor receptor (PDGFR), and parathyroid hormone receptor (PTHR)53. Through these 
protein interactions, NHERF1 plays central roles in signaling complex assembly and receptor 
recycling as well as in establishing cell polarity and directing protein trafficking23. However, 
NHERF1 by itself, with only two PDZ domains, has a limited capacity to form multiprotein 
arrays or scaffold interactive proteins within membrane microdomains54. 
 Notably, some PDZ domains, including the NHERF1 PDZ domains, can increase their 
scaffolding capacity through PDZ oligomerization with the same or different PDZ-containing 
proteins. Oligomerization of InaD through the third and fourth PDZ domains of separate InaD 
proteins has been shown to amplify the capacity and complexity of InaD-sequestered proteins in 
the Drosophila phototransduction networks54. Dimerization of ZO PDZ2 domains has been 
proposed to play a pivotal role in initiating claudin polymerization and directing tight junction 
strands for correct localization55. Analysis of over 150 PDZ domains in mouse genome revealed 
that 30% of mouse PDZ domains participate in PDZ–PDZ interactions, suggesting that many PDZ 
domains have evolved as a dual binding module in facilitating the formation of multiprotein 
complexes56. For NHERF1, both PDZ1 and PDZ2 can dimerize with homologous PDZ–PDZ 
interactions being more prominent than heterologous interactions54. The homodimerization of 
NHERF1 PDZs has been suggested to provide a mechanism for NHERF1 to expand its capacity 
in multiprotein complex assembly and regulating the activity of interacting proteins within 
membrane microdomains54. It should be noted that the PDZ1 and PDZ2 domains of NHERF1 
exhibit distinct binding specificity: for example, both CXCR2 and PLCβ2 prefer to bind to 
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PDZ242,57. It is conceivable that the assembly of the CXCR2– NHERF1–PLCβ2 signaling complex 
in neutrophils may not only require the PDZ canonical ligand-binding ability, but also the ability 
of NHERF1 to engage in separate PDZ–PDZ interactions. Consequently, such non-canonical PDZ-
binding mode could have important implications in CXCR2–PLCβ2 coupling and in CXCR2- 
mediated neutrophil chemotaxis. In this context, we here present the crystal structure of NHERF1 
PDZ2 in complex with the CXCR2 C-terminal peptide TSTTL. The structure reveals the PDZ2–
CXCR2 interaction specificity and two probable modes of PDZ2 dimerization. The structure also 
suggests a model that the PDZ2 dimerization utilizes a distinct interface that functions together 
with two well-separated canonical ligand-binding pockets in scaffolding multiprotein complex 
formation. 
Materials and Methods 
Protein Expression and Purification 
 A DNA fragment encoding the human NHERF1 PDZ2 (residues 155–234) was amplified 
by PCR using the full-length human NHERF1 cDNA as a template. The C-terminal extension 
TSTTL that corresponds to residues 356–360 of human CXCR2 was created by inclusion of 15 
extra bases in the reverse primer. The PCR products were cloned in the pSUMO vector containing 
an N-terminal His6-SUMO tag. The resulting clone was transformed into Escherichia coli BL21 
Condon Plus (DE3) cells for protein expression. The transformants were grown to an OD600 
(optical density at 600 nm) of 0.4 at 37 _C in LB medium, and then induced with 0.1 mM 
isopropylthio-β-D-galactoside at 15 °C overnight. The cells were harvested by centrifugation and 
lysed by French Press. The soluble fraction was then subjected to Ni2+ affinity chromatography 
purification, followed by the cleavage of the His6-SUMO tag with yeast SUMO Protease 1. PDZ2 
proteins were separated from the cleaved tag by a second Ni2+ affinity chromatography and further 
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purified by size-exclusion chromatography. Finally, the proteins were concentrated to 10–20 
mg/ml in a buffer containing 20 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1 mM b-mercaptoethanol, 
and 5% glycerol. 
Crystallization, Data Collection and Structure Determination 
 Crystals were grown by the hanging-drop vapor-diffusion method by mixing the protein 
(20 mg/ml) with an equal volume of a reservoir solution containing 100 mM Tris–HCl, pH 8.5, 
8% PEG8000 at 20 °C. Crystals typically appeared overnight and continued to grow to their full 
size in 2–3 days. Prior to X-ray diffraction data collection, crystals were cryoprotected in a solution 
containing the mother liquor and 25% glycerol and flash cooled in liquid nitrogen. The data were 
collected at 100 K at beamline 21-ID-F at the Advanced Photon Source (Argonne, IL) and 
processed and scaled using the program XDS58. Crystals belong to the space group P21 with two 
molecules in the asymmetric unit (Table 1). The structure was solved by the molecular replacement 
method with the program PHASER59 using the PDZ2–TETSL structure (PDB code: 2OZF) as a 
search model. Structure modeling was carried out in COOT60, and refinement was performed with 
PHENIX61. To reduce the effects of model bias, iterative-build OMIT maps were used during 
model building and structure refinement. The final models were analyzed and validated with 
Molprobity62. All figures of 3D representations of the PDZ2–CXCR2 structure were made with 
PyMOL (www.pymol.org). 
Protein Data Bank accession number 
 Coordinates and structure factors have been deposited in the Protein Data Bank with 
accession number 4Q3H. 
Results and Discussion 
Structural Basis of the PDZ2-CXCR2 Interaction 
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Table 1. Crystallographic data and refinement statistics 
Data  
Space group P21 
Cell parameters  
a, b, c (Å) 32.8, 55.3, 54.2 
β (°) 90.7 
Wavelength (Å) 0.97856 
Resolution (Å) 32.8-1.44 (1.49-1.44) 
Rmergea 0.042 (0.369)b
 
Redundancy 3.5 (2.7) 
Unique reflections 28,239 
Completeness (%) 96.8 (78.2) 
I/ 17.8 (2.3) 
Refinement  
Resolution (Å) 32.8-1.44 (1.49-1.44) 
Molecules/AU 2 
Rwork
c 0.166 (0.254) 
Rfree
d 0.197 (0.304) 
Ramachandran plot  
Residues in favored 98.3% 
Residues in allowed 1.7% 
RMSD  
Bond lengths (Å) 0.007 
Bond angels () 1.12 
No. of atoms  
Protein 1299 
Peptide 72 
Water 249 
B-factor (Å2)   
Protein 24.1 
Peptide 20.2 
Water 33.4 
 
aNumbers in parentheses refer to the highest resolution shell. 
bRmerge= Σ|I-I| / ΣI, where I is the observed intensity and I is the averaged intensity of 
multiple observations of symmetry-related reflections. 
cRwork= Σ|Fo-Fc| / Σ|Fo|, where Fo is the observed structure factor, Fc is the calculated structure 
factor. 
dRfree was calculated using a subset (5%) of the reflection not used in the refinement. 
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Figure 1. Structure of NHERF1 PDZ2 in complex with the CXCR2 C-terminal sequence 
TSTTL. (A) Ribbon diagram of the PDZ2–CXCR2 structure. PDZ2 is shown in orange and the 
CXCR2 peptide is shown in blue. Secondary structures of PDZ2, a-helices, and b-strands are 
labeled and numbered according to their position in the sequence. (B) Surface representation 
of the PDZ2–CXCR2 structure. Surface coloring is according to the electrostatic potential: red, 
white, and blue correspond to negative, neutral, and positive potential, respectively. The 
vacuum electrostatics/protein contact potential was generated by PyMOL. The CXCR2 peptide 
is depicted by sticks. (C) Stereo view of the PDZ2 ligand-binding site bound to the CXCR2 C-
terminal peptide. PDZ2 residues are represented by sticks with their carbon atoms colored in 
orange. The CXCR2 peptide is depicted by sticks overlaid with 2Fo _ Fc omit map calculated 
at 1.44 Å and contoured at 1.8 r. Hydrogen bonds are illustrated as red broken lines. (D) 
Sequence alignment of selected PDZ domains. The alignment was performed by ClustalW5, 
including human NHERF1 and NHERF2. Identical residues are shown as white on black, and 
similar residues appear shaded in cyan. Secondary structure elements are displayed above the 
sequences and labeled according to the scheme in A. Sequence numbering is displayed to the 
left of the sequences, with every 10th residue marked by a dot shown above the alignment. (For 
interpretation of the references to color in this figure legend, the reader is referred to the web 
version of this article.) 
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 The overall structure of NHERF1 PDZ2 is similar to other PDZ domains3,63, consisting of 
six b strands (β1–β6) and two α-helices (αA and αB) (Fig. 1A and B). The CXCR2 peptide binds 
in the cleft between β2 and αB, burying a total solvent-accessible surface area of 649 Å2. The 
binding specificity of the PDZ2–CXCR2 interaction is achieved through networks of hydrogen 
bonds and hydrophobic interactions (Fig. 1C). At the ligand position 0, the side chain of Leu0 is 
nestled in a deep hydrophobic pocket formed by invariant residues Tyr164, Phe166, and Leu168 
from β2 and Val216 and Ile219 from αB (Fig. 1D). In the pocket, the position of Leu0 is further 
secured by both a hydrogen bond from its amide nitrogen to the Phe166 carbonyl oxygen and 
triplet hydrogen bonding between the Leu0 carboxylate and the amides of Tyr164, Gly165, and 
Phe166. Similar interactions have been observed in several other PDZ-mediated complexes3,63, 
which represent the most-conserved binding mode for terminal Leu recognition. Residues at other 
peptide positions also contribute to the PDZ2– CXCR2 complex formation (Fig. 1C). At position 
–1, the side chain hydroxyl of Thr-1 forms a hydrogen bond with the Nδ2 atom of the Asn167 side 
chain. At position –2, Thr-2 makes one hydrogen bond to the His212 imidazole group and two 
hydrogen bonds to the highly conserved residue Leu168. At the ligand position –3, the interactions 
with Ser-3 include one hydrogen bond from its side chain hydroxyl to the Oδ1 atom of Asn167, 
and another hydrogen bond to the Nδ1 atom of Asn167. The latter two interactions represent PDZ2 
specific interactions, as Ser-3 recognition in PDZ1–CXCR2 is mediated by a His residue at His169 
position2. Finally, the peptide residue Thr-4 engages in a main-chain contact with Ser170, but does 
not participate in any specific side-chain interactions. These observations indicate that the last four 
residues of CXCR2 contribute to the binding specificity in the PDZ2–CXCR2 complex formation. 
Differential CXCR2 Interaction with PDZ1 and PDZ2 
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 To gain further insight into PDZ2 binding specificity, we compared the PDZ2–CXCR2 
structure to the structure of the NHERF1 PDZ1–CXCR2 complex. The overall structures of the 
two liganded PDZs are very similar, with a root mean square difference (RMSD) of 1.02 Å for 83 
Ca atoms (Fig. 2A). The main chains of the bound peptides superimpose well (RMSD of 0.15 Å), 
as do their relative spatial positions to the conserved PDZ motifs. In addition, the ligand 
recognition modes at the peptide positions 0 and –2 are virtually indistinguishable, characterized 
by structurally similar binding sites composed with completely conserved residues (Figs. 2B and 
1D). However, substantial differences are observed in the ligand recognition at positions –1 and –
3. Note these differences are associated directly with the only residue difference in their peptide-
binding pockets. In PDZ1, the residue His at position 27 is replaced by Asn at the matching 
position (167) in PDZ2. As a result of this difference, Thr-1 does not hydrogen bond to the His27 
side chain in PDZ1, instead of forming a general, rather ligand indiscriminative Van der Waals 
interaction (Fig. 2B). At position –3, no direct contacts are observed between Ser-3 and His27 in 
DZ1–CXCR2. This contrasts to the PDZ2–CXCR2 complex where the side chain of Asn167 
adopts a different rotamer that allows direct hydrogen bonding with the Ser-3 hydroxyl (Fig. 1C). 
Specific interaction of Ser-3 with Asn167 in PDZ2–CXCR2, but not with His27 in PDZ1–CXCR2, 
is consistent with previous affinity selection experiments in which PDZ2 almost exclusively 
selected ligands with Ser at position -3 from random peptides, whereas PDZ1 showed no apparent 
preference for this position64.  
Probable Modes of PDZ2 Dimerization 
 Both NHERF1 PDZ1 and PDZ2 can dimerize, and their dimerization has been suggested 
to facilitate the formation of multiprotein complexes and contributes to NHERF1-mediated 
intracellular signaling54. However, the molecular details of NHERF1 PDZ dimerization are 
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unknown. Examination of the crystal packing reveals two probable modes of PDZ2 dimerization. 
As shown in Fig. 3A and B, both dimers are generated by a twofold symmetry. Dimer 1 is  
generated by the parallel stacking of helix αB from both monomers, while dimer 2 is generated by 
the interactions between two copies of strands β1, β4, and β6. In dimer 1, the buried surface area 
at the dimer interface is 497 Å2, which is comparable to 592 Å2 calculated for dimer 2. However, 
residues that form the dimer interface are only conserved in dimer 2 but not in dimer 1 (Figs. 3 
and 1D). For dimer 1, the interactions at the interface include a salt-bridge between Lys210 and 
Asp214, two water-mediated hydrogen bonds between Asp214 and Ser217, and three stacking 
Figure 2. Structural comparison of NHERF1 PDZ2 and PDZ1. (A) Superposition of the 
structures of PDZ2–CXCR2 (orange–blue; PDB code: 4Q3H) and PDZ1–CXCR2 (green–gray; 
PDB code: 4JL7). PDZ domains are represented by ribbons. Residues in the ligands are 
displayed as sticks. (B) Superposition of the PDZ ligand-binding pockets. Both PDZ and ligand 
residues are depicted by sticks and colored according to the scheme in A. (For interpretation of 
the references to color in this figure legend, the reader is referred to the web version of this 
article.)  
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interactions involving Asp214, Ser217, Arg220, and Ala221 (Fig. 3C). Because this interface is 
based on the twofold symmetry, the intermolecular interactions are contributed in the same way 
by both monomers in stabilizing the dimer structure. For dimer 2, the interactions at the interface 
include a salt bridge between Arg151 and Glu201 and the hydrophobic interactions between 
Pro152, Leu154, and Leu229 from both monomers (Fig. 3D). Although Arg153 is not directly 
involved in this interface, its side chain guanidinium makes three intramolecular hydrogen bonds 
to Asp197 and Gly192, which stabilize the conformation of the interface-forming b1 strand in 
dimer 2. It is of particular interest to note that NHERF1 R153Q mutation was recently found in 
patients who have impaired renal phosphate reabsorption65. Subsequent studies demonstrated that 
this disease mutation abolished NHERF1 dimerization but did not disrupt its interaction with 
the parathyroid hormone 1 receptor66. While future studies are required to demonstrate the 
biological significance of the crystallographically observed dimerization, the high degree of 
conservation and the close proximity of the disease-related mutation suggest that the interface 
observed in dimer 2 might have some physiological relevance. In this regard, only dimer-2 model 
is considered further. 
 In dimer 2, the canonical target-binding pockets are located at the distal sides of the dimer 
interface. They are arranged in a parallel fashion and related by the same twofold symmetry present 
at the dimer interface (Fig. 3B). In the dimer, the CXCR2 peptides are clearly resolved in both 
pockets, with the binding conformations highly similar to those observed in the monomeric PDZ–
ligand complexes (Fig. 2A). This indicates that the dimerization does not affect the PDZ2–peptide 
binding in the crystal, or the binding sites in the dimer are open to allow the interaction with the 
target proteins. This observation is also consistent with the previously proposed model that PDZ 
dimerization utilizes a distinct interface that functions together with two well-separated canonical 
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ligand-binding pockets in scaffolding multiprotein complex formation67. 
Structural Diversity in PDZ Dimerization 
 In addition to the NHERF1 PDZ domains, other PDZ domains capable of dimerization 
include GRIP (glutamate receptor interacting protein) PDZ6, SHANK (SH3 and multiple ankyrin 
repeat domains protein) PDZ, and ZO (zonula occludens protein) PDZ268-70. Like NHERF1 
oligomerization, the ability of these PDZ domains to dimerize has been suggested to expand PDZ 
scaffolding capacity and facilitate the formation of multiprotein complexes67. In line with this 
suggestion, recent family-wide proteomic investigation demonstrated that PDZ dimerization is 
surprisingly abundant, with ~30% mouse PDZ domains engaging in PDZ–PDZ interactions56. 
Figure 3. Two probable modes of PDZ2 dimerization. (A) Overall view of dimer 1 and (B) 
dimer 2. (C) Close-up view of the interactions in dimer 1 and (D) dimer 2. PDZ backbones are 
represented by ribbons with monomers colored green and orange. CXCR2 peptides are depicted 
by ribbons and shown in blue. Interacting residues at the dimer interface are depicted by sticks. 
Secondary structural elements are marked as in Fig. 1A. (For interpretation of the references to 
color in this figure legend, the reader is referred to the web version of this article.) 
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Interestingly, PDZ–PDZ interactions appear to be substantially more selective than interactions 
between PDZ domains and the C termini of their target proteins56. Modeling studies based on 
large-scale binding data predicted that one PDZ domain, on average, interacts with 245 different 
proteins via C-termini, contrasting only 1.7 PDZ domains via dimerization56. This suggests that 
the non-canonical binding mode contributes more to defining the precise composition of protein 
complexes than does the canonical binding mode56. 
 Structurally, the high selectivity of PDZ–PDZ interactions is manifested by highly distinct 
dimerization modes and substantially different dimer interfaces. For example, in GRIP PDZ6, the 
dimer interface is formed primarily by the N-terminal β1 strand and parts of the β4–αA loop, 
whereas in ZO PDZ2 domain, the dimerization occurs via a domain-swapping mechanism, with 
β1 and β2 protruding out and exchanged between two symmetry related monomers (Fig. 4). In 
 
 
contrast, the dimer interface in SHANK PDZ involves both β1 and two distinct loops of β2–β3 
and β5–αB, which effectively define a new mode of PDZ dimerization. It is also interesting to note 
that the orientation of two canonical ligand-binding pockets in the NHERF1 PDZ2 dimer is unique  
among the known PDZ structures. In NHERF1 PDZ2, the ligands are orientated parallelly, 
whereas in other PDZ dimers the two ligands are positioned in an antiparallel fashion (Figs. 3B 
Figure 4. Structural diversity in PDZ dimerization. Ribbon representation of the (A) GRIP 
PDZ6 dimer (PDB code: 1N7F), (B) ZO PDZ2 dimer (PDB code: 2RCZ), and (C) SHANK 
PDZ dimer (PDB code: 1Q3P). PDZ monomers are shown in green and orange. Target peptides 
are shown in blue. Structural elements involved in PDZ dimerization are indicated. (For 
interpretation of the references to color in this figure legend, the reader is referred to the web 
version of this article.) 
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and 4). Therefore, these observed differences demonstrate the structural diversity in PDZ 
dimerization, consistent with prior suggestion that diverse PDZ–PDZ interactions have been 
optimized as a mechanism in scaffolding the formation of distinct multiprotein complexes56. This 
also highlights the potential importance of the present study, as it provides an additional example 
of how PDZ domains may dimerize and could be valuable in understanding NHERF1 complex-
scaffolding function in neutrophils and also in CXCR2-related diseases. 
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CHAPTER 3 STRUCTURAL INSIGHTS INTO PDZ-MEDIATED INTERACTION OF 
NHERF2 AND LPA2, A CELLULAR EVENT IMPLICATED IN CFTR CHANNEL 
REGULATION 
 
 *Published in Biochem Biophys Res Commun. 2014 March 28; 446(1): 399–403. 
doi:10.1016/j.bbrc.2014.02.128. All authors agreed with including their work in this dissertation 
Abstract 
 The formation of CFTR-NHERF2-LPA2 macromolecular complex in airway epithelia 
regulates CFTR channel function and plays an important role in compartmentalized cAMP 
signaling. We previously have shown that disruption of the PDZ-mediated NHERF2-LPA2 
interaction abolishes the LPA inhibitory effect and augments CFTR Cl- channel activity in vitro 
and in vivo. Here we report the first crystal structure of the NHERF2 PDZ1 domain in complex 
with the C-terminal LPA2 sequence. The structure reveals that the PDZ1-LPA2 binding specificity 
is achieved by numerous hydrogen bonds and hydrophobic contacts with the last four LPA2 
residues contributing to specific interactions. Comparison of the PDZ1-LPA2 structure to the 
structure of PDZ1 in complex with a different peptide provides insights into the diverse nature of 
PDZ1 substrate recognition and suggests that the conformational flexibility in the ligand binding 
pocket is involved in determining the broad substrate specificity of PDZ1. In addition, the structure 
reveals a small surface pocket adjacent to the ligand-binding site, which may have therapeutic 
implications. This study provides an understanding of the structural basis for the PDZ-mediated 
NHERF2-LPA2 interaction that could prove valuable in selective drug design against CFTRrelated 
human diseases.  
Introduction 
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 Cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-regulated 
chloride (Cl-) channel primarily localized at the apical surfaces of epithelial cells lining the airway, 
gut and exocrine glands71,72. CFTR is responsible for transepithelial salt and water transport and 
plays critical roles in maintaining fluid homoeostasis, airway fluid clearance, and airway 
submucosal glands secretion in both healthy and disease phenotypes73,74. Growing evidence 
suggests that CFTR interacts directly or indirectly with other ion channels, transporters, 
scaffolding proteins, protein kinases, effectors, and cytoskeletal elements to form macromolecular 
complexes at specialized subcellular domains44,75. These dynamic protein-protein interactions 
regulate CFTR channel function as well as its localization and processing within cells37,76. We 
have shown that CFTR, lysophosphatidic acid receptor 2 (LPA2), and Na+/H+ exchanger 
regulatory factor-2 (NHERF2) form macromolecular complexes at the plasma membrane of gut 
epithelia, which functionally couple LPA2 signaling to CFTR-mediated Cl- transport41. LPA2 is a 
G protein-coupled receptor that binds the lipid signaling molecule LPA and mediates diverse 
cellular responses such as cell proliferation and platelet aggregation77. NHERF2 is a PDZ domain-
containing protein that typically functions as a scaffold to cluster transporters, receptors, and 
signaling molecules into supramolecular complexes78. We have demonstrated that LPA inhibits 
both CFTR-mediated Cl- transport through the LPA2-mediated Gi pathway in a 
compartmentalized manner in cells and CFTR-dependent cholera toxin-induced mouse intestinal-
fluid secretion in vivo41. We also demonstrated that disruption of the PDZ-mediated NHERF2-
LPA2 interaction abolishes the LPA inhibitory effect and augments CFTR Cl- channel activity in 
Calu-3 cells and also in fluid secretion from pig tracheal submucosal glands79. These findings 
imply that targeting the PDZ-mediated NHERF2-LPA2 interaction could provide new strategies 
for therapeutic interventions of CFTR-associated diseases76,79. 
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 In general, PDZ domains mediate protein interactions by recognizing the C-terminal 
sequence of target proteins and binding to the targets through a canonically and structurally 
conserved PDZ peptide-binding pocket23. Based on the residues at positions 0 and -2 of the 
peptides (position 0 referring to the C-terminal residue), early studies have grouped PDZ domains 
into two major specificity classes: class I, (S/T)X(V/I/L) (X denoting any amino acid); class II, 
(F/Y)X(F/V/A)3,52,80. However, more recent mounting evidence indicates that PDZ specificity is 
unexpectedly complex and diverse, with the PDZ domain family recognizing up to seven C-
terminal ligand residues and forming at least 16 unique specificity classes81. The complexity of 
PDZ-peptide interactions is further exemplified by the facts that many PDZ domains can bind to 
multiple ligands of different peptide classes and that single peptides are capable of binding to 
distinct PDZ domains81. This complex picture of PDZ-peptide interactions raises a challenging 
problem regarding how PDZ domains, structurally simple protein-interaction modules, achieve 
binding promiscuity and specificity concomitantly, the nature of which remains obscure. In this 
context, we present the crystal structure of NHERF2 PDZ1 in complex with the LPA2 C-terminal 
peptide MDSTL. The structure reveals that the LPA2 peptide binds to PDZ1 in an extended 
conformation with the last four residues making specific side chain contacts. Comparison of the 
PDZ1-LPA2 structure to the structure of PDZ1 in complex with a different peptide suggests that 
the binding diversity of PDZ1 is facilitated by the conformational flexibility in the peptide-binding 
pocket. This study provides the structural basis of the PDZ-mediated NHERF2-LPA2 interaction 
and could be valuable in the development of novel therapeutic strategies against CFTR-related 
human diseases. 
Materials and Methods 
Protein Expression and Purification 
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 A DNA fragment encoding the human NHERF2 PDZ1 (residues 9–90) was amplified by 
PCR using the full-length human NHERF2 cDNA as a template. The C-terminal extension 
MDSTL that corresponds to residues 347–351 of human LPA2 was created by inclusion of 15 
extra bases in the reverse primer. The PCR products were cloned in the pSUMO vector containing 
an N-terminal His6-SUMO tag. The resulting clone was transformed into Escherichia coli BL21 
Condon Plus (DE3) cells for protein expression. The transformants were grown to an OD600 
(optical density at 600 nm) of 0.4 at 37 °C in LB medium, and then induced with 0.1 mM 
isopropylthio-β-D-galactoside at 15 °C overnight. The cells were harvested by centrifugation and 
lysed by French Press. The soluble fraction was then subjected to Ni2+ affinity chromatography 
purification, followed by the cleavage of the His6-SUMO tag with yeast SUMO Protease 1. PDZ1 
proteins were separated from the cleaved tag by a second Ni2+ affinity chromatography and further 
purified by size-exclusion chromatography. Finally, the proteins were concentrated to 20–30 
mg/ml in a buffer containing 20 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1 mM β-mercaptoethanol 
(BME), and 5% glycerol. 
Crystallization, Data Collection and Structure Determination 
 Crystals were grown by the hanging-drop vapor-diffusion method by mixing the protein 
(~20 mg/ml) with an equal volume of a reservoir solution containing 100 mM HEPES, pH 7.0, 0.2 
M potassium thiocyanate (KSCN), 25% PEG3350 at 20 °C. Crystals typically appeared overnight 
and continued to grow to their full size in 2–3 days. Prior to X-ray diffraction data collection, 
crystals were cryoprotected in a solution containing the mother liquor and 25% glycerol and flash 
cooled in liquid nitrogen. The data were collected at 100 K at beamline 21-ID-F at the Advanced 
Photon Source (Argonne, IL) and processed and scaled using the program XDS58. Crystals belong 
to the space group P21 with unit cell dimensions a = 26.4 Å, b = 40.3 Å, c = 37.1 Å, β = 107.4°, 
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and one molecule in the asymmetric unit (Table 2). The structure was solved by the molecular 
replacement method with the program PHASER59 using the PDZ1-EDTSV structure (PDB code: 
2OCS) as a search model. Structure modeling was carried out in COOT60, and refinement was 
performed with PHENIX61. To reduce the effects of model bias, iterative-build OMIT maps were 
used during model building and structure refinement. The final models were analyzed and 
validated with Molprobity62. All figures of 3D representations of the PDZ1-LPA2 structure were 
made with PyMOL (www.pymol.org). 
Protein Data Bank Accession Number 
 Coordinates and structure factors have been deposited in the Protein Data Bank with 
accession number 4POC. 
Results and Discussion 
Specificity Determinants of NHERF2-LPA2 Interaction 
 The overall structure of NHERF2 PDZ1 is similar to other PDZ domains3,63, consisting of 
six β-strands (β1–β6) and two α-helices (αA and αB) (Fig. 5A and B). The LPA2 peptide binds in 
the cleft between β2 and αB, burying a total solvent-accessible surface area of 472 Å2. The binding 
specificity of the PDZ1-LPA2 interaction is achieved through networks of hydrogen bonds and 
hydrophobic interactions (Fig. 5C). At the ligand position 0, the side chain of Leu0 is nestled in a 
deep hydrophobic pocket formed by invariant residues Tyr21, Phe23, and Leu25 from β2 and 
Val73 and Ile76 from αB (Fig. 5D). In the pocket, the position of Leu0 is further secured by both 
a hydrogen bond from its amide nitrogen to the Phe23 carbonyl oxygen and triplet hydrogen 
bonding between the Leu0 carboxylate and the amides of Tyr21, Gly22, and Phe23. Similar 
interactions have been observed in several other PDZ-mediated complexes3,63, which represent the 
most-conserved binding mode for terminal Leu recognition. Residues at other peptide positions  
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Table 2. Crystallographic data and refinement statistics 
Data  
Space group P21 
Cell parameters  
a, b, c (Å) 26.4, 40.3, 37.1 
Wavelength (Å) 1.2719 
Resolution (Å) 24.2-1.34 (1.37-1.34) 
Rmergea 0.039 (0.250)
b 
Redundancy 4.1 (4.0) 
Unique reflections 17966 
Completeness (%) 99.8 (99.6) 
I/ 15.3 (3.0) 
Refinement  
Resolution (Å) 24.2-1.34 (1.37-1.34) 
Molecules/AU 1 
Rwork
c 0.145 (0.268) 
Rfree
d 0.177 (0.275) 
Ramachandran plot  
Residues in favored 97.9% 
Residues in allowed 2.1% 
RMSD  
Bond lengths (Å) 0.007 
Bond angels () 1.2 
No. of atoms  
Protein 1347 
Peptide 73 
Water 143 
Chloride 2 
B-factor (Å2)   
Protein 17.2 
Peptide 17.7 
Water 33.4 
Chloride 20.2 
SCN 12.4 
 
aNumbers in parentheses refer to the highest resolution shell. 
bRmerge= Σ|I-I| / ΣI, where I is the observed intensity and I is the averaged intensity of 
multiple observations of symmetry-related reflections. 
cRwork= Σ|Fo-Fc| / Σ|Fo|, where Fo is the observed structure factor, Fc is the calculated structure 
factor. 
dRfree was calculated using a subset (5%) of the reflection not used in the refinement. 
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also contribute to the PDZ1-LPA2 complex formation (Fig. 5C). At position -1, the side chain 
hydroxyl of Thr-1 forms a hydrogen bond with the Nδ1 atom of the His24 imidazole ring. At 
position -2, Ser-2 makes one hydrogen bond to the His69 imidazole group and two hydrogen bonds 
to the highly conserved residue Leu25. At the ligand position -3, the interactions with Asp-3 
include one hydrogen bond from its side chain carboxylate to the side chain of His24 and another 
hydrogen bond to the Nδ1 atom of His26. The latter interaction represents an unusual variation in 
Figure 5. Structure of NHERF2 PDZ1 in complex with the LPA2 C-terminal sequence MDSTL. 
(A) Ribbon diagram of the PDZ1-LPA2 structure. PDZ1 is shown in light blue and the LPA2 
peptide is shown in green. Secondary structures of PDZ1, α-helices, and β-strands are labeled 
and numbered according to their position in the sequence. (B) Surface representation of the 
PDZ1-LPA2 structure. Surface coloring is according to the electrostatic potential: red, white, 
and blue correspond to negative, neutral, and positive potential, respectively. The vacuum 
electrostatics/protein contact potential was generated by PyMOL. The LPA2 peptide is depicted 
by sticks. (C) Stereo view of the PDZ1 ligand-binding site bound to the LPA2 Cterminal 
peptide. PDZ1 residues are represented by sticks with their carbon atoms colored in light blue. 
The LPA2 peptide is depicted by sticks overlaid with 2Fo − Fc omit map calculated at 1.34 Å 
and contoured at 1.8 σ. Hydrogen bonds are illustrated as red broken lines. (D) Sequence 
alignment of selected PDZ domains. The alignment was performed by ClustalW5, including 
human NHERF1 and NHERF2. Identical residues are shown as white on black, and similar 
residues appear shaded in cyan. Secondary structure elements are displayed above the 
sequences and labeled according to the scheme in Figure 1A. Sequence numbering is displayed 
to the left of the sequences, with every 10th residue marked by a dot shown above the alignment. 
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this structure, since the negatively charged Asp-3 is generally recognized by an Arg residue at 
Arg37 position in other PDZ complexes4. Finally, the peptide residue Met-4 engages in a main-
chain contact with Gly27, but does not participate in any specific side-chain interactions. These 
observations indicate that the last four residues of LPA2 contribute to the binding specificity in 
the PDZ1-LPA2 complex formation. 
Structural Basis for Broad PDZ1 Binding Specificity 
 To gain further insights into PDZ1 binding specificity, we compared the PDZ1-LPA2 
structure to the structure of PDZ1 in complex with a different peptide (EDTSV) (Fig. 6). The 
overall structures of the two liganded PDZs are very similar, with a root mean square difference 
(RMSD) of 0.20 Å for 85 Cα atoms (Fig. 6A). The main chains of the bound peptides superimpose 
well (RMSD of 0.16 Å), as do their relative spatial positions to the conserved PDZ motifs. These 
observations indicate that binding of different peptides has little effect on the PDZ1 overall fold, 
consistent with previous evidence that the localized changes at a few key positions within HtrA1 
PDZ are responsible for dramatically altered PDZ binding specificity63. Close examination of the 
structural alignment reveals some similarities, but also substantial differences, in the peptide- Val0 
follow a similar path entering a pocket that is virtually identical between the two PDZ1 structures. 
At the ligand position -2, recognition of Ser-2 and Thr-2 is achieved by similar mechanisms where 
there is a direct hydrogen bond to the side chain of the structurally conserved His69 in both cases. 
However, large differences are observed around the residues at the -1 position of the ligands (Fig. 
6C). In PDZ1-LPA2, His24 adopts a single conformation that simultaneously binds to Thr-1 and 
Asp-3. In PDZ1-EDTSV, His24 has a double conformation in which binding pockets (Fig. 6B). 
At the ligand position 0, the side chains of LPA2 Leu0 and EDTSV conformation 1 is similar to 
the one observed for PDZ1-LPA2, but conformation 2 represents a new conformer with the side  
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chain packing against the hydroxyl of Ser-1. This conformational change is accompanied by large 
alteration in the Arg38 rotameric states. In PDZ1-EDTSV, the side chain of Arg38 points away 
from the bound peptide, whereas in PDZ1-LPA2 it adopts a double conformation with one 
conformation oriented toward the Thr-1 residue. These observed differences suggest that the 
conformational changes of His24 and Arg38 underlie the NHERF2 PDZ1 flexibility to 
accommodate ligands with different -1 side chains and denote a structural explanation for diverse 
peptide recognition. 
Drug Design Perspective and Novel SCN Binding Site 
Figure 6. Structural comparison of NHERF2 PDZ1 domains. (A) Superposition of the structures 
of PDZ1–LPA2 (light blue; PDB code: 4P0C) and PDZ1-EDTSV (orange; PDB code: 2OCS). 
PDZ domains are represented by ribbons. Residues in the ligands are displayed as sticks. 
Carbon atoms are shown in green for LPA2 and in gray for EDTSV. (B) Superposition of the 
PDZ1 ligand-binding pockets. Both PDZ1 and ligand residues are depicted by sticks and 
colored according to the scheme in Fig. 2A. (C) Close-up view of structural differences of 
His24 and Arg38. Red broken lines represent hydrogen bonds between His24 and LPA2. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the web 
version of this article.) 
. 
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 CFTR protein is the product of the CFTR gene mutated in patients with CF, which is a 
lethal autosomal-recessive genetic disease that is most common among Caucasians82. We 
previously have suggested that targeting the NHERF2-LPA2 interaction may have a therapeutic 
potential in CF treatment, as inhibition of this interaction has been found to be sufficient to enhance 
CFTR channel activity both in vitro and in vivo76,79. These previous findings highlight the 
significance of our present structure studies and also imply that the structural details of the 
NHERF2-LPA2 interaction may be valuable in developing new methods and strategies for 
selective drug design. For instance, this information can be used to create new NHERF2 inhibitors 
that are potent and specific to block the NHERF2-LPA2 interaction. Such inhibitors have the 
potential to rescue epithelial cell function in the human CF airway by restoring or increasing CFTR 
channel activity. However, it should be noted that NHERF2 is capable of binding to a multitude 
of ligands, through which it regulates many cellular processes essential to normal physiological 
functions, such as testicular differentiation, signal transduction, endosomal recycling, membrane 
targeting, and hormone receptor desensitization83-86. It is therefore conceivable that the 
engagement of an inhibitor with the ligand-binding site would interfere with the full spectrum of 
NHERF2 PDZ-target interactions and could lead to considerable risks with a diverse range of 
unwanted physiological and hormonal abnormalities. In order to achieve NHERF2 inhibitor 
selectivity, one possible solution to this challenge is designing partially competitive inhibitors that 
only affect ligand-specific interactions and bind to a site other than the ligand-binding pocket. In 
this regard, it is interesting to note that the present structure reveals a small surface pocket adjacent 
to the ligand binding site (Fig. 7). This pocket is identified based on an extra electron density 
observed at the surface of the PDZ1 structure (Fig. 7A). Based on the components in the crystal  
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condition and the shape of the density, the density was assigned as a thiocyanate molecule (SCN). 
Residues contributing to SCN binding include His26 from β2, Gly53 from β4, and Phe35 and 
Arg37 from β3 (Fig. 7B). Note that residues His26 and Arg37 shared by the ligand binding site  
 
and the SCN binding site are highly conserved (Fig. 5D), and these sites have been implicated in 
ligand-specific interactions in other PDZ domains2,87. Therefore, strategies aiming at exploiting 
the novel SCN binding site may represent a promising approach to achieve NHERF2-inhibitor 
selectivity that would allow the differentiation among a wide range of NHERF2-
mediatedinteractions. Such strategy should have important implications in specific NHERF2 
scaffolding regulation and also in many CFTR-dependent human diseases. 
 
 
Figure 7. SCN binding pocket. (A) Surface representation of the SCN binding site. PDZ1 
surface is colored in light blue. LPA2 residues are represented by sticks with their carbon atoms 
colored in green. SCN is depicted by balls-and-sticks overlaid with 2Fo − Fc omit map 
calculated at 1.34 Å and contoured at 1.8 σ. (B) Putative SCN-interacting residues. PDZ1 
residues are shown in light blue and LPA2 residues are shown in green. SCN is depicted by 
spheres. (For interpretation of the references to colour in this figure legend, the reader is referred 
to the web version of this article.) 
. 
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CHAPTER 4 PDZ STRUCTURE AND IMPLICATION IN SELECTIVE DRUG DESIGN 
AGAINST CYSTIC FIBROSIS 
 
 *Published in Curr Drug Targets. 2015;16(9):945-50. All authors agreed with including 
their work in this dissertation. 
Abstract 
 PDZ domains play an essential role in a number of cellular processes by facilitating protein 
scaffolding and assembly of protein complexes. These domains consist of 80 to 90 amino acids 
and are found to recognize short C-terminal sequences of target proteins. Protein complex 
formation between PDZ target molecules can lead to a number of signaling and regulatory cascades 
that may either promote or inhibit the activation of certain proteins. It has been shown that the 
interaction of the PDZ domains of NHERF2 with LPA2 plays an inhibitory role on the cystic 
fibrosis transmembrane conductance regulator (CFTR) by promoting the assembly of a CFTR–
NHERF2–LPA2 complex. CFTR regulates chloride ion transport across the epithelial plasma 
membrane, and individuals possessing CFTR mutations show decreased protein function and 
consequently, viscous mucus accumulation due to improper fluid transport. This type of ailment 
is termed cystic fibrosis. Thus, insight to the structure of PDZ domains and how they function to 
form macromolecular complexes could be therapeutically important in augmenting CFTR channel 
activity in cystic fibrosis patients. Here we review the PDZ domain family while dissecting their 
structure, function and implications in CFTR regulation and cystic fibrosis.  
CFTR and Cystic Fibrosis 
 Cystic fibrosis transmembrane conductance regulator (CFTR) is a glycoprotein encoded 
by the CFTR gene that is 230 kb in length coding for 1480 amino acids consisting of 6 domains: 
two transmembrane domains (MSD), two nucleotide binding domains (NBD), regulatory “R” 
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region, and a PDZ interacting motif88,89. CFTR is a member of the ABC transporter ATPase family 
and allows for the transmembrane flow of chloride ions (Cl−) down the electrochemical gradient88. 
Such anion flow is critical for proper water balance between the extracellular and intracellular 
space of epithelial cells in the gastrointestinal tract, pulmonary tract, and ducts lining organs such 
as the pancreas, testes, and sweat glands71-74. Without proper water flow, mucus lining of these 
tracts becomes dehydrated and accumulate in these areas clogging ducts and giving rise to bacterial 
infections especially in the lungs90,91. Improper function of this channel can be caused by a variety 
of mutations with F508del being the most common92,93. This deletion results in the improper 
folding of the protein and consequently its degradation before it reaches the plasma membrane of 
epithelial cells94-97. Other mutations may result in a protein that is translocated to the membrane 
but in reduced number or functionality98,99. Such mutation resulting in these complications is 
termed cystic fibrosis. 
 Cystic fibrosis is perceived commonly by its associated symptoms such as difficulty 
breathing, respiratory infections, poor growth, and infertility100. Much is known about what causes 
the disease including allelic specific mutations and the mechanism in which chloride ion transport 
is affected100,101. Yet, even with the wide understanding of how the disease is manifested among 
humans, there is currently no cure for the illness and only limited therapeutics when it comes to 
treatment. Additionally, those diagnosed are only predicted to have an average life expectancy of 
37 to 40 years102. Some of the current treatment options for chronic infections resulting from the 
disease include mucolytics, antibiotics, and potential lung transplantation as the disease 
worsens103-107. However, emerging studies suggest possible roles of other proteins in CFTR 
regulation. Interaction with transporters, ion channels, and scaffolding proteins regulates CFTR 
function at specialized subcellular domains37,76,108,109. The formation of a macromolecular complex 
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between CFTR, Na+/H+ exchanger regulatory factor-2 (NHERF2), and lysophosphatidic acid 
receptor 2 (LPA2) links CFTR-mediated Cl− transport to LPA2 signaling at the gut epithelial 
membrane41. It has been shown that the NHERF2–LPA2 interaction is mediated by PDZ domains 
and inhibition of this interaction abolishes the inhibitory effect of LPA resulting in a significant 
increase in CFTR channel activity. This inhibition was also found to stimulate fluid secretion in 
pig submucosal glands in the trachea79. Such promising findings not only offer insight into 
potential therapeutic targets for this challenging disease but additionally, provide a foundation for 
rational drug design in order to more effectively treat cystic fibrosis. 
NHERF Function and Involvement in CFTR Regulation 
 Na+/H+ exchanger regulatory factor (NHERF) proteins are protein adaptors that have been 
shown to be highly expressed in epithelial tissue78. The adaptor function of these proteins is due 
to the presence of two PDZ domains at the N-terminus and a C-terminal ezrin-radixin-moesin 
(ERM) binding domain that binds cytoskeletal proteins34. The functional consensus of NHERF 
family proteins is that they are able to mediate the formation of multiprotein complexes involving 
membrane and non-membrane proteins. The NHERF-scaffolded protein complexes are important 
in cell metabolism and growth33,110,111. One of these membrane proteins targeted by NHERF, 
commonly expressed in epithelial tissue, is CFTR. NHERF proteins have been demonstrated to be 
essential for CFTR function because they have been shown to stabilize CFTR in the plasma 
membrane and prevent endocytotic-targeted degradation by CFTR-associated ligand (CAL)112. 
Thus, proper NHERF–CFTR interaction is essential in promoting correct CFTR function and 
proper anion transport across epithelial membranes. However, PDZ-mediated NHERF interaction 
has also been shown to be a negative regulator in some biological processes and produce inhibitory 
effects on certain proteins including CFTR41,44,75,113. This dual regulatory role presents a degree of 
34 
 
 
 
difficulty when therapeutically targeting such proteins. Therefore, a structural understanding of 
NHERF-PDZ binding specificity may allow for a more selective targeting and a better prediction 
of how certain therapeutics could affect specific cellular processes. 
 The NHERF family consists of four members with NHERF1 and NHERF2 being the most 
similar and well known114. NHERF1 has been shown to be particularly important in cellular 
signaling by promoting interleukin 8 receptor, beta (CXCR2)-mediated neutrophil migration2. 
NHERF1 was also found to regulate CXCR2 function during spinal cord development and is 
essential for controlling positions of oligodendrocyte precursor cells2,47. CXCR2 is a G-protein 
coupled receptor whose signaling has been well established46,115. In neutrophils, CXCR2 signaling 
requires the complex formation between CXCR2 and phospholipase C (PLC)-β2, a downstream 
effector of intracellular signaling2. The formation of this complex has been shown to be dependent 
on the PDZ domains of NHERF1 which bridge the two molecules by interacting with the PDZ-
binding motif at their C-terminus2. The same type of interaction was observed for CXCR2–PLCβ3, 
which is required for tumor proliferation in pancreatic cancer cells116. However, scaffolding 
mediated by the PDZ domains of NHERF2 in the CFTR–LPA2 complex formation has been 
shown to inhibit CFTR function, and disrupting this complex using a cell-permeable LPA2-
specific peptide was able to restore CFTR-dependent anion efflux41. Therefore, examination of the 
structural properties of PDZ domain-containing proteins, especially NHERF2, could provide new 
therapeutic avenues for the treatment of CFTR-associated diseases including cystic fibrosis. 
PDZ Domains 
 PDZ domains are evolutionarily conserved domains present in numerous signaling 
proteins. These domains are found not only in animals and plants but also yeast and bacteria117. 
The acronym PDZ is derived from the first three proteins originally found to contain such a 
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domain. These three proteins are known as Postsynaptic density protein 95kD (PSD95), 
Drosophila disc large tumor suppressor (Dig1), and Zonula occludens-1 protein (ZO-1)22. In 
general, PDZ domains recognize and mediate protein interactions through small motifs localized 
at the C-terminus of target proteins23. Protein recognition by the PDZ domain is important for 
assembling signal complexes, recycle receptors, protein trafficking, and instituting cell 
polarity23,52. To date, two types of PDZ domains are well studied, class I and class II. Peptides with 
a consensus sequence (S/T)X(V/I/L) (X denoting any amino acid) and (F/Y)X(F/V/A) form the 
class I and class II groups respectively52,80. Structural insight into PDZ domains revealed an overall 
and conserved fold of six strands (β1–β6) and two α-helices (αA and αB)1,2,43,52,80,87,116. In addition, 
a similar peptide recognition mode is shared among all the PDZ domains. The 0 peptide residue 
(C-terminal residue) resides inside a hydrophobic pocket and the −2 peptide residue forms a 
specific hydrogen bond with a conserved residue1,52,80. Despite the similarity of peptide 
recognition, recent data indicate that PDZ binding is more complex than previously thought. 
Altogether, the PDZ domain family can recognize and bind to seven C-terminal ligand residues 
and form sixteen distinctive specificity classes81. Additionally, the ability of PDZ domains to bind 
to different classes of ligands and one ligand capable of binding to different PDZ domains highlight 
the complexity of PDZ-mediated interactions81. Although PDZ domains are structurally simple 
protein interaction modules, PDZ–peptide interactions create a challenging question to how 
binding promiscuity and specificity are concurrently achieved. The mechanism to address this 
problem is still not well understood.  
PDZ Structure 
 PDZ1 and PDZ2 are each found in NHERF1 and NHERF2. Both domains share multiple 
conserved residues with a great level of sequence similarity2. The overall folds of these domains 
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are similar with two α-helices (αA and αB) and six β-strands (β1–β6) forming an evolutionally 
conserved fold (Fig. 8A)1. Crystal structures of PDZ1– CXCR2, PDZ1–CFTR, PDZ1–PDGFR, 
and PDZ1–β2AR are well superimposed. Pairwise RMSDs (root-mean-square differences) range 
from 0.33 to 0.64 Å for entire Cα atoms (Fig. 8B)2. In all structures, the peptide ligands bind inside 
the β2 and αB cleft. The backbones of the bound peptides and their relative spatial positions to the 
PDZ motifs are highly superimposed with an RMSD range of 0.09 to 0.15 Å. This indicates that 
the overall PDZ fold has little change upon peptide binding. Consistently, previous results show 
that localized changes in a few key areas of the PDZ fold were sufficient to alter specificity in PDZ 
binding2,63. The PDZ1 structural comparison provides additional supportive evidence for this 
observation. Only the peptide-binding pocket shows significant changes, particularly for PDZ 
residues interacting with peptide ligands at −1 and −3 positions. As shown in Figure (8C), the side 
chain of Asp22 has two different orientations, and the side chain of Glu43 has four different 
orientations. This demonstrates the conformational flexibility in the PDZ peptide-binding pocket, 
and more importantly, this flexibility explains how the PDZ domain binds the −1 ligand residue 
with different polarity and hydrophobicity2,4,87,116.  
 In order to advance our understanding into NHERF2 PDZ1 binding specificity, the 
structure of PDZ1–LPA2 and PDZ1 bound to a different peptide (EDTSV) was compared1.  
Structural comparison of these domains revealed some similarities and considerable differences in 
the peptide-binding pockets (Fig. 9A). The side chains of LPA2 Leu0 and EDTSV Val0 follow a 
similar path at the ligand position 0 entering a pocket that is virtually identical between the two 
PDZ1 structures. At the −2 ligand position, Ser-2 and Thr-2 are recognized by similar mechanisms 
where a direct hydrogen bond forms to structurally conserved His69 side chain in both cases. 
However, residues around the −1 ligand position have noticeable differences. (Fig. 9B). In PDZ1– 
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LPA2, His24 simultaneously interacts with Thr-1 and Asp-3 under a single conformation, whereas 
in PDZ1–EDTSV, His24 has two conformations in which the first conformation is observed in 
PDZ1–LPA2 and the second conformation presents the side chain packing against the hydroxyl of 
Ser-1. Additionally, a large change in the Arg38 rotameric state is coupled to the second 
conformation. In PDZ1–EDTSV, the Arg38 side chain points away from the bound peptide, 
whereas in PDZ1–LPA2, Arg38 adopts two conformations with one conformation oriented near 
the Thr-1 residue. These observed differences suggest that the conformational changes of His24 
and Arg38 may contribute to NHERF2-PDZ1 binding promiscuity and allow for recognition of 
peptides with different −1 side chains1. 
Drug Design Perspective: Cystic Fibrosis 
 As demonstrated for NHERF1 bridging of CXCR2 and PLCβ along with NHERF2 
bridging of CFTR and LPA21,49,79, specific interruption of certain PDZ-mediated interactions 
Figure 8. Structures of NHERF1 PDZ1 domain. (A) Ribbon illustration of PDZ1–CXCR2. 
PDZ1 and the CXCR2 peptide are represented in yellow and green, respectively. PDZ 
secondary structures are labeled based on their location in the sequence. (B) Structural 
alignment of PDZ1–CXCR2 (yellow; PDB code: 4JL7)2, PDZ1–CFTR (green; PDB code: 
1I92)3, PDZ1–β2AR (blue; PDB code: 1GQ4)4, and PDZ1–PDGFR (magenta; PDB code: 
1GQ5)4. PDZ domains are depicted by ribbons, while ligand residues are represented as sticks. 
(C) Structural alignment of PDZ1 pockets important for ligand binding. Ligand and PDZ 
residues are represented by sticks and colored according to the scheme in B. 
38 
 
 
 
could prove to be therapeutic in augmenting the normal function of certain proteins. Since previous 
studies have found such interruption to be sufficient in promoting CFTR channel activity41,44,75, 
the targeting of PDZ in NHERF2 by pharmacological approaches might provide optimistic 
treatment for patients suffering from cystic fibrosis. Inhibition of the NHERF2–LPA2 interaction 
by the small molecule CO-068 elevates cAMP levels in proximity to CFTR and upregulates CFTR 
channel activity79. This proof-of-concept study demonstrates that CFTR Cl- channel function can 
be fine-tuned by pharmacological approaches through modulating PDZ-mediated interactions 
within the CFTR-containing protein complexes. While the cellular effects of CO-068 has been 
thoroughly addressed82, current findings underline the structural significance of PDZ domains. 
Better understanding the NHERF2–LPA2 interface may prove worthwhile in rational drug design. 
For instance, structural data can promote the development of potent NHERF2 inhibitors 
specifically designed to interrupt the NHERF2–LPA2 interaction. Inhibitors of the NHERF2–
LPA2 interface may possess potential to rescue epithelial cell function in the human CF airway by 
increasing or restoring CFTR channel activity. However, it should be noted that NHERF2 is 
capable of binding to numerous ligands that are involved in several physiological processes such 
as signal transduction, testicular differentiation, membrane targeting, endosomal recycling, and 
hormone receptor desensitization83-85. The use of non-selective inhibitors to disrupt NHERF2–
LPA2 interface will likely interrupt the NHERF2 interaction network setting the stage for 
physiological complications at considerable risk. Thus, alternative targeting strategies may be 
necessary in order to produce beneficial therapeutic outcomes without a vast array of side effects. 
 In order to achieve selectivity in NHERF2 inhibition, one practical option is the use of 
partially competitive inhibitors. Ideally, such inhibitors must not directly target the PDZ binding 
site but should be able to engage ligand-specific binding residues through a separate nearby pocket.  
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The structural analysis of the NHERF2 PDZ1–LPA2 complex suggests a potential site for such 
targeting strategy. In the PDZ1–LPA2 structure, a small surface pocket was found in close 
proximity to the ligand-binding site (Fig. 9C)1. This pocket is occupied by a thiocyanate molecule 
Figure 9. Crystal structure of NHERF2 PDZ1–LPA2 complex. (A) Structural alignment of 
PDZ1–LPA2 (green; PDB code: 4POC)1 and PDZ1–EDTSV (yellow; PDB code: 2OCS). 
Ribbons depict the PDZ domain, and ligand residues are exhibited as sticks. Carbon atoms are 
shown in grey for LPA2 and in blue for EDTSV. (B) Structural alignment of the PDZ1 ligand-
binding pockets. PDZ1 and ligand residues are colored according to the scheme in A and 
represented as sticks. (C) View of His24 and Arg38 structural differences. Red broken lines 
represent hydrogen bonds between His24 and LPA2. (D) Surface representation of the SCN 
binding site. PDZ1 surface is colored in green. LPA2 residues are colored in grey and 
represented as sticks. 2Fo − Fc omit map (calculated at 1.34 Å and contoured at 1.8 σ) overlays 
SCN depicted as balls-and-sticks. (E) Putative SCN-interacting residues. PDZ1 residues are 
represented in green and LPA2 residues are represented in grey. SCN is depicted by spheres. 
(The color version of the figure is available in the electronic copy of the article). 
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(SCN) from crystallization conditions. Residues contributing to SCN binding include His26 from 
β2, Gly53 from β4, and Phe35 and Arg37 from β3 (Fig. 9D). The residues His26 and Arg37 are 
shared by both the ligand-binding site and SCN binding site. Interestingly, these two residues have 
been implicated in ligand-specific interactions in other PDZ domains2,116. Therefore, strategies 
aiming at exploiting the SCN binding site may represent a promising approach to achieve 
NHERF2–inhibitor selectivity and allow for ligand differentiation among a wide range of 
NHERF2-mediated interactions. 
Concluding Remarks 
 From the promotion of CXCR2-mediated neutrophil migration to stabilization of CFTR in 
the cytoplasmic membrane of epithelial cells, the PDZ domains of NHERF proteins are imperative 
for promoting the proper functioning of membrane proteins in various cellular processes. 
However, the fact that NHERF2 bridging of LPA2 and CFTR has a negative impact on CFTR 
channel activity suggests a complex role of NHERF2 in CFTR regulation. While targeting the 
NHERF2-mediated LPA2–CFTR interaction is an attractive therapeutic option for cystic fibrosis, 
PDZ binding promiscuity makes such a targeting strategy seem intangible, as the substrate-binding 
site of PDZ domains may not be feasible for selective drug design. Nevertheless, high-resolution 
structures of PDZ domains are now leading insight in alternative strategies for such proteins. In 
the case of PDZ1 of NHERF2, small molecule binding motifs adjacent to the peptide recognition 
sequence may serve as a viable target for small molecule inhibitors. This not only would be 
beneficial for augmenting CFTR activity in cystic fibrosis patients but also potentially provide 
insight into the treatment of other diseases involving PDZ-containing proteins. 
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PART II 
Insight into Structural Properties of the Nogo-b Receptor and Eluding the Bottleneck of 
Crystallography  
CHAPTER 5 SOLUTION STRUCTURE OF THE TRANSMEMBRANE NOGO-B 
RECEPTOR AND INSIGHT INTO ITS TOPOLOGICAL ORIENTATIONS BY SMALL 
ANGLE X-RAY SCATTERING ANALYSIS 
 
Abstract 
 The Nogo-B Receptor (NgBR) is newly identified class I transmembrane receptor known 
for its role in binding Nogo-B and promoting angiogenesis by chemotaxis in vivo. Most recently 
we discovered that NgBR shows binding specificity for the farnesylated oncoprotein Ras and 
facilitates Ras activation by recruitment to the plasma membrane. To understand the potential 
mode of interaction with farnesylated Ras, we performed Small Angle X-ray Scattering (SAXS) 
analysis of the NgBR construct 79–293 which includes the currently accepted cytosolic and 
transmembrane domains with a portion of the extracellular region. SAXS analysis reveals the 
radius of gyration (Rg) for our NgBR construct to be 18.2 Å with a maximum end to end distance 
(Dmax) of 61 Å. Ab initio modeling returns a globular molecular envelope with an estimated 
molecular weight of 23 kD closely correlated with the calculated molecular weight of our NgBR 
construct. These data indicate that our NgBR construct is well folded which exists as a globular 
domain in solution with no apparent intrinsic disordered regions. However, this result is conflicting 
with the currently accepted topological orientation of NgBR which would separate our NgBR 
construct into three distinct domains: extracellular, transmembrane and cytosolic domains. 
However, comparison of the molecular envelope structure of our NgBR construct with the 
structure of Undecaprenyl Pyrophosphate Synthase (UPPs) which shares similar sequence 
homology to NgBR, further supports our conclusion that the regions included in our construct are 
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folded into a single globular domain, as the two structures are highly superimposed. This led us to 
propose the idea that NgBR may exist in more than one topological orientation and that the 
currently accepted transmembrane domain may internalize and contribute to the overall fold of 
NgBR cytosolically. Altogether, our SAXS analysis provides the first molecular envelope structure 
of the Nogo-B Receptor and provides evidence for a topological orientation of NgBR not 
previously identified. 
Introduction 
 The Nogo-b Receptor (NgBR) is a transmembrane receptor protein that has been found to 
localize to the plasma membrane as well as the endoplasmic reticulum (ER). Since its identification 
in 2006, there has been increasing investigation of NgBR due its medical relevance in cholesterol 
trafficking, cardiovascular disease, cancer, and Ras signaling. NgBR was first identified due to its 
interaction with Nogo-B, a protein that plays a major role in the development of vasculature of 
endothelial cells118. NgBR has also shown to play an influential role in embryogenesis. 
Experiments performed by Park and colleagues demonstrated that the knockout of NgBR leads to 
lethality in mouse embryos due to free intracellular cholesterol accumulation and defective 
regulation of protein glycosylation119. Due to its role in vasculogenesis, it has also been shown to 
be critically involved in tumor growth and cancer metastasis. NgBR has been specifically 
demonstrated to show increased expression in breast cancer which has been proven essential for 
EGF signaling in breast cancer cells contributing to both tumor growth and size120. Furthermore, 
we have recently proven that NgBR is able to bind the farnesylated oncoprotein Ras and recruit it 
to the plasma membrane for activation120. As is generally understood, the farnesylation of the 
CAAX box of Ras is required for its subsequent localization to the plasma membrane leading to 
Ras activation120-123. Furthermore, we showed that the farnesylation of Ras is essential for NgBR 
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binding to Ras and NgBR does not bind to the unfarnesylated Ras protein120. Interestingly, NgBR 
shares significant sequence identity to the cis-isoprenyl transferase family and maintains conserved 
residues responsible in the binding of farnesyl diphosphate (FPP)120,124-126. Thus, it is possible that 
NgBR and cis-isoprenyl transferase family may share a similar structural mechanism in binding to 
farnesyl groups. 
 The Nogo-B Receptor is a 293 residue type 1 receptor protein with three primary domains: 
a cytoplasmic domain consisting of residues ~140-293, a single transmembrane region with 
residues ~120-139, and an extracellular domain containing residues ~47-119 with a putative 46 
residue signaling sequence on the N-terminus127. NgBR has also been found to adopt alternate 
topological conformations with its C-terminal domain existing in either the cytosol or lumen of 
the ER. In the ER, NgBR has been found to bind and stabilize Nieman-Pick type C2 protein 
(NPC2) consequently facilitating cholesterol homeostasis128. However, its major topological 
orientation appears to consist of its C-terminal domain existing cytosolically. In the cytosol, it has 
been shown to promote human cis-isoprenyl transferase (hCITase) activity therefore facilitating 
dolicol synthesis129. NgBR’s C-terminal domain has been shown to share significant sequence 
similarity to the cis-IPTase family with upward of 44% with cis-IPTase of Micrococcus luteus129. 
This protein family is found to bind isoprenyl lipids and catalyze condensation of isopentenyl 
diphosphate to farnesyl diphosphate (FPP). However, even with high sequence similarity, NgBR 
does not possess such activity118. NgBR has also been shown to contain conserved residues with 
an additional cis-IPTase, undecaprenyl pyrophosphate synthase (UPPs). UPPs is a lipid carrier for 
peptidoglycan that synthesizes UPP and is responsible for synthesis of the bacterial cell wall126. 
UPPs has also been shown to bind and catalyze the condensation of isopentenyl diphosphate to 
FPP126. The binding of UPPs to its substrates is mediated the presence of a hydrophobic pocket at 
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the core of the protein. In case of its interaction with FPP, binding is manifested by hydrophobic 
interactions occurring between FPP farnesyl group and residues L85 and L88 of the α-3 helix. 
Interestingly, these farnesyl interacting residues are conserved with the two residues (I117 and 
L120) of NgBR required for H-Ras binding. Therefore, if NgBR was to fold similar to UPPs, it 
could be possible that NgBR shares a similar structural mechanism to that of UPPs for farnesyl 
binding.  
 The structure of NgBR is currently unknown and is likely due to its lack of solubility or its 
disordered nature127. Both the full-length recombinant protein as well as its individual domains 
have been shown to possess limited solubility upon expression. Previous studies using 
bioinformatics, CD spectroscopy, and NMR have been used to characterize NgBR’s individual 
domains127. Such data suggests that NgBR’s cytosolic domain is only partially folded and its 
extracellular region intrinsically disordered, although no structural information has yet been 
determined. In this study, we circumvent this issue by the development of a new expression 
construct for NgBR. In our construct, we include residues corresponding to the entire cytosolic 
domain of NgBR with the inclusion of its transmembrane domain and some extracellular 
components. This is rationalized based on its sequence similarity to the UPPs and the hypothesis 
that NgBR may exhibit a similar structural mechanism as UPPs for farnesyl binding. The resulting 
expression of the recombinant protein demonstrates that NgBR exhibits good solubility and is 
primarily monomeric based on size exclusion chromatography (SEC). Additionally, small angle 
x-ray scattering (SAXS) analysis reveals the recombinant protein is well folded with a similar 
shape and size to that of UPPs and is verified by the calculated radius of gyration (Rg), Parod 
volume, and Dmax of the SAXS data. Furthermore, SAXS analysis demonstrates that the 
recombinant monomeric NgBR protein consisting of residues 79-293 is able fold as a single 
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globular domain in solution. However, this result conflicts with the currently accepted topology of 
NgBR in the plasma membrance which would separate our construct into three domains. Because 
NgBR has been shown to adopt alternate topological conformations in ER membrane, it is possible 
a similar topological change occurs at the plasma membrane allowing residues in our construct to 
fold into a single domain. Therefore, this would implicate the need for NgBR to adopt a topological 
orientation not yet identified.  
Materials and Methods 
Sequence Alignment and Modeling  
 Identification of proteins possessing structural data with sequence identity similar to NgBR 
was carried out using Basic Local Alignment Search (BLAST) of the Protein Data Bank (PDB). 
Manual alignment of NgBR with UPPs was then performed to identify conserved residues in which 
may be critical to NgBR’s structure. Conserved residues exhibiting potential structural 
implications were then determined by based on the structure of UPPs (PDB code 1X08). Residues 
identified as potentially critical to NgBR’s overall fold based on UPPs structural analysis were 
then included in the NgBR expression construct. 
Protein Expression and Purification 
 The open reading frame corresponding to human NgBR (79-293) was amplified and cloned 
into a pCDF-SUMO vector containing an His6-SUMO tag. The vector was transformed into 
BL21(DE3) cells for recombinant protein expression. Cells were inoculated into LB media 
supplemented with 34 μg/mL streptomycin and grew to an optical density of 0.5. Induction growth 
was carried out in 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 15°C overnight. 
Harvested cells were lysed using a French press, spun down, and the supernatant was pooled for 
purification. The supernatant was passed through a HisTrap column (GE Healthcare), and eluted 
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out. Yeast SUMO protease (ULP1) was added to pooled fractions containing His6-SUMO-NgBR 
(79-293) and incubated overnight to remove His6-SUMO tag. The pooled fractions passed through 
HisTrap column again, and the native NgBR (79-293) was collected from the flowthrough and 
wash. NgBR (79-293) was further purified by HiLoad 16/60 Superdex 200 column in 20 mM Tris 
pH 7.5, 150 mM NaCl and 5% glycerol. 
Small Angle X-Ray Scattering Data Collection and Analysis 
 Small Angle X-ray Scattering (SAXS) data was collected at Argonne National Laboratory 
beamline ID18. Prior to data collection, samples were dialyzed with buffer [20mM HEPES pH 
7.5, 150 mM NaCl, 5% glycerol, 1mM TCEP] overnight, and centrifuged at 13,000g for 10 
minutes at 4°C. 20 mg/mL NgBR was injected into S200 column [GE Heathcare]. Scattering 
frames corresponding to monomer NgBR were scaled, averaged and subtracted from averaged 
buffer frames. The NgBR (79-293) monomer scattering curve was analyzed using the ATSAS 
suite. PRIMUS and GNOM were used to measure the radius of gyration and maximum radius 
(Dmax), respectfully. DAMFILT was used to generate a dummy atom model of NgBR (79-293) 
monomer. 
Results 
BLAST Analysis and Expression Construct Identification 
 BLAST analysis of the Protein Data Bank was carried out using the amino acid sequence 
corresponding to human NgBR. The top result returned was that of the E. coli cis-IPTase 
Undecaprenyl Pyrophosphate Synthase (UPPs) containing 24% sequence identity and 39% 
sequence similarity. Structural analysis of UPPs (PDB code 1X08) reveals an overall composition 
consisting of ten α-helices and six β-strands (Fig. 10B). Further analysis of the structure reveals 
the compound farnesyl pyrophosphate (FPP) secured deep in a hydrophobic tunnel formed by 
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helices α-1 and α-3 along with the β-1 strand of UPPs (Fig. 10B). FPP is further secured by 
hydrophobic interactions by leucine 85 and leucine 88 of the α-3 helix (side chains depicted in 
yellow). Upon manual alignment of NgBR with UPPs, NgBR is found to possess conserved 
residues corresponding to all α-helices and all β-strands apart from the first β-strand (β0) found in 
UPPs (Fig. 10A). Additionally, NgBR residues I117 and L120 are conserved with two FPP 
interacting residues (L85 and L88) of the UPPs crystal structure (Fig. 10A and 10B). Interestingly, 
residues conserved by NgBR with the UPPs α1, α2, α3, and β1 regions are found to compose 
NgBR’s transmembrane domain and part of its extracellular domain. This presents problem if 
NgBR was to fold similar to that of UPPs. If NgBR was to exhibit similar structure to UPPs, these 
regions would need to be present in the cytosol and does not agree with the current topological 
oreintations of NgBR 127,129. However, if the conserved residues were removed from the UPPs 
structure (Fig 1B, segments in red), it is unlikely that NgBR would be able to fold correctly based 
on the UPPs model (Fig. 10C). Thus, due to these observations, an expression construct (residues 
79-293) was created for NgBR encompassing all conserved residues with that of UPPs.  
Expression and Purification of NgBR 
 Residues 79-293 of NgBR were cloned and expressed as described in the methods. As can  
be observed, NgBR achieves good expression as shown by SDS-PAGE with a solid band at 
~36.5kDa in the induced cell culture corresponding to the expected molecular weight of the 
construct plus the His6-SUMO tag (Fig. 11A). Additionally, over 50% of total recombinant NgBR 
present in the cell lysis appears to be recovered in the supernatant fraction (Fig 11A). 
Comparatively, we tested an additional construct in which included residues corresponding to 
NgBR’s cytosolic region (137-293). As can be observed, NgBR achieves good expression with 
the solid band observed at ~32.5 kDa in the induced cell culture corresponding to NgBR with  
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attached His6-SUMO tag (Fig 11B). However, when assessing the latter constructs solubility, 
NgBR is virtually non-existent in the supernatant fraction with comparison to the total cell lysate  
Figure 10. Modeling the NgBR–HRas interaction. (A) Sequence alignment of NgBR and 
Undecaprenyl pyrophosphate synthase (UPPs). NgBR and UPPs share 24% sequence identity 
and 39% sequence similarity. Such a level of sequence similarity suggests that the overall fold 
of NgBR may be similar to that of UPPs. Identical residues are shown as white on black, and 
similar residues appear shaded in cyan. Secondary structure elements in UPPs are displayed 
above the sequences and numbered according to their position in the sequence. Sequence 
numbering is displayed to the left of the sequences. (B) Crystal structure of UPPs (PDB code: 
1X08) in complex with a farnesyl diphosphate (FPP) (blue). The secondary structure elements 
involved in FPP binding are colored in red. (C) UPPs structure with residues of UPPs 
corresponding to NgBR’s transmembrane region with part of its extracellular domain removed 
resulting in eradication of the FPP binding site and likely reduction of UPPs structural integrity.  
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(Fig. 11B). This suggests that inclusion of the additional residues in the prior construct appears to 
enhance the recombinant protein solubility.  
 Following expression, the NgBR construct (79-293) was purified as described in the 
methods. Upon subjection to Ni2+ affinity purification, NgBR appears to be eluted around 38% 
elution buffer (Fig. 12A) which is verified by SDS-PAGE exhibiting distinct bands at ~36.5 kDa 
corresponding to the expected molecular weight of NgBR with the His6-SUMO tag (Fig. 12B). 
Following the first nickel column, the protein fractions were pooled and His6-SUMO tag was then 
removed by protease digestion with yeast ULP1. The cleaved protein mixture was then subjected  
Figure 11. Expression test for NgBR constructs. (A) NgBR expression construct 79-293 which 
included NgBR’s cytosolic domain along with its transmembrane and some of its extracellular 
region. Expression is noted in the induced cell culture with the band corresponding to the NgBR 
construct + SUMO tag at ~36.5 kDa. Following cell lysis NgBR is observed in the total cell 
lysate fraction composed of both soluble and insoluble protein fractions. Upon centrifugation, 
NgBR (~60% as compared to the total cell lysate) is observed in the supernatant suggesting that 
over half of the expressed protein demonstrates good solubility. (B) Expression and solubility 
analysis of NgBR residues corresponding to its cytosolic domain (137-293). Expression is 
noted for NgBR + SUMO tag with protein band observed at ~32.5 kDa. Following cell lysis, 
NgBR is observed in the total cell lysate fraction but upon centrifugation, little to no soluble 
protein is recovered in the supernatant fraction suggesting that residues present in the 79-293 
construct aid in the solubility of NgBR’s cytosolic domain.    
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to a second round of nickel purification to remove the His6-SUMO tag. Purified NgBR was then 
subjected to size exclusion chromatography (SEC) in the last step of purification. As can be 
observed by the SEC chromatogram, four distinct peaks are noted by UV detection (Fig. 12C). 
Molecular weight estimations by elution volume suggests the largest peak at ~90 ml corresponds 
Figure 12. Purification of the NgBR (79-293) construct. (A) Chromatogram of the first Nickel 
affinity column. NgBR is eluted around 38% elution buffer (%B, green). (B) SDS-PAGE 
fractions from the first Nickel affinity purification. As can be observed, the protein band 
corresponding to NgBR + His6-SUMO tag at ~36.5 kDa is present in fractions A10-B4. 
Fractions A11-B4 were then pooled and subjected to protease cleavage of the His6-SUMO, 
followed by a second round of Nickel purification in order to remove any additional protein 
contaminants. (C) Further purification of NgBR by size exclusion chromatography. As can be 
seen by the chromatogram, NgBR exists primarily as a monomer based on its elution peak at ~ 
90 ml. Tetrameric NgBR appears to be the second most prevalent species based on the observed 
peak around 76 ml. Some NgBR dimer is observed at ~80 ml but appears to be the least 
prevalent species in solution. Some NgBR protein is noted in the SEC void volume at 46 ml 
which suggests that NgBR displays some non-specific aggregation in solution.  
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to NgBR in the monomeric state. Based on UV absorbance, this appears to be the majority of the 
species in solution. The next largest peak is observed at ~76 ml and consistent with the molecular 
weight corresponding to NgBR in the tetrameric state. Additionally, a small population of dimeric 
NgBR is observed at ~80 ml but appears to be the population minority. Furthermore, final peak at 
46 ml corresponds to the void volume of the column in which is typically composed of protein or 
other large molecular aggregates. Some NgBR is found to be present in the void suggesting that 
the recombinant NgBR protein exhibits a certain degree of non-specific aggregation. However, 
SDS-PAGE of SEC fraction (Fig. 12D) demonstrates that NgBR is able to be purified with 
virtually no additional protein contamination suitable for successive structural analysis.    
Small Angle X-ray Scattering Analysis  
 Following purification, NgBR’s structural properties were elucidated using biophysical 
characterization by Small Angle X-ray Scattering (SAXS). In order to ensure monodispersity of 
the sample, an inline SAXS data collection approach was implemented. Concentrated NgBR (20 
mg/ml) consisting of monomer, dimer, and tetrameric states were subjected to size exclusion 
chromatography with tandem protein diffraction upon elution from the column. Of the data 
collected, SAXS analysis was conducted for NgBR’s monomeric state. Correction of background 
scattering of the SEC buffer was performed by subtraction in which resulted in the scattering curve 
for NgBR as seen in blue (Fig. 13A). For comparison, the CRYOSOL-generated scattering of 
UPPs (solid red line) was overlaid with scattering data of monomeric NgBR (Fig. 13A). As can be 
observed, NgBR’s subtraction curve follows the theoretical scattering of UPPs very well at low q 
range suggesting that NgBR may exhibit an overall structure similar to that of UPPs. At increasing 
q values, slight variation is noted between NgBR scattering and UPPs. Such an observation may 
implicate that NgBR exhibits some higher resolution structural differences with UPPs. The Kratky  
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plot of NgBR’s subtraction curve (Fig. 13B), demonstrates a similar pattern with lower q values 
of NgBR following closely to UPPs theoretical scattering. Again, overlay of UPPs scattering with 
Figure 13. Small angle X-ray scattering analysis. (A) Subtraction scattering curve of NgBR 
(blue) overlay with theoretical scattering of UPPs (solid red line). NgBR scattering appears to 
follow closely to that of UPPs at low q values with slight variation at higher q suggesting that 
NgBR may share a similar fold to that of UPPs with potential high resolution structural 
differences. (B) Kratky plot representation of NgBR scattering. NgBR scattering (blue) exhibits 
a smooth bell shaped curve with higher q values averaging near base line characteristic of a 
well folded macromolecule in solution. (C) Pair distribution curve (P(r)) for NgBR. NgBR 
exhibits a smooth bell shape curve which is characteristic of a globular macromolecule in 
solution. (D) DAMFILT ab initio dummy atom model of NgBR. Modeling of SAXS data for 
NgBR using the program DAMFILT reveals a molecular envelope solution structure of NgBR 
(blue). Superposition of UPPs structure (PDB code 1X08) (green) demonstrates that UPPs 
superimposes well suggesting that the NgBR (79-293) expression construct folds similar to that 
of UPPs as a globular molecule in solution.   
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NgBR at high q implicates some possible variation. However, scattering as depicted by NgBR’s 
Kratky plot exhibits an overall curve representative of a well folded macromolecule in solution. 
This is determined by the smooth bell shaped scattering curve of NgBR with higher q values 
averaging near baseline, characteristic of a well folded protein in solution130.  
 The experimental Radius of gyration (Rg) value for NgBR is calculated to be 18.2 which 
closely coincides with the Rg of UPPS (18.6). Such a correlation implies that the recombinant 
NgBR protein exhibits a similar overall size to UPPs. This is further verified by the analysis of 
NgBR’s pair distribution function. The maximum end to end distance (Dmax) of NgBR is calculated 
to be 61 similar to UPPs Dmax of 58.61. NgBR’s similarity in size to UPPs is more so confirmed 
by analysis of the Parod volume calculated to be 7.22 and 6.76 for NgBR and UPPs respectively.  
Additionally, NgBR exhibits a smooth bell shaped p(r) curve which is characteristic of a globular 
macromolecule in solution (Fig. 13C). Finally, ab initio modeling of the SAXS data as performed 
by the program DAMFILT reveals the first in solution molecular envelope structure of NgBR (Fig. 
13D) with calculated molecular weight (MW) to be 22.96 kDa. This is consistent with the 
estimated MW for the NgBR construct of 24.13 kDa. Upon superposition of the UPPs crystal 
structure with the NgBR molecular envelope, it is observed that UPPs superimposes very well with 
some possible differences in the α-6, α-7, and α-8 segments of UPPs (Fig. 10B and 13D). However, 
though is likely that NgBR and UPPs do exhibit some structural differences, SAXS analysis 
verifies that the recombinant monomeric NgBR protein consisting of residues 79-293 is able fold 
as a single globular domain in solution.  
Discussion 
 Recently, there has been growing interest in the nogo-b receptor due to its therapeutic 
implications in a variety of human diseases. However, its limited structural information due to 
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complications in solubility has been the bottleneck in its biophysical characterization. 
Additionally, the ability of NgBR to adopt varying topological conformations further complicates 
the development of an appropriate expression construct. The current study provides evidence for 
potential circumvention of this issue. By inclusion of residues sharing conservation with UPPs, 
our data suggests that incorporation of NgBR’s transmembrane domain with part of its 
extracellular region increases recombinant protein solubility. This observation may in turn open 
potential opportunities for future high resolution structural studies of the nogo-b receptor. 
Additionally, SAXS analysis confirms that our protein construct is able to fold as a single globular 
domain in solution. However, these data do not agree with the topological orientations of NgBR 
noted in the literature which would separate our construct into three domains: cytosolic, 
transmembrane, and extracellular. This may implicate that NgBR is able to adopt a topological 
conformation not yet identified. Upon some physiological stimulus, NgBR could experience a 
dynamic structural change where residues included in our construct internalize and fold with its 
cytosolic domain. Similar instances of domain transition have been noted in the literature. Multiple 
cases have been observed where membrane proteins were found to adopt varying topological 
conformations due to alteration in the phospholipid environment131-134.  It has been specifically 
demonstrated in the case of E. coli LacY where deficiency of phosphatidylethanolamine (PE) 
results in the inversion of its N-terminal six transmembrane domain α-helical bundle. 
Consequently, this inversion results in the translocation of its seventh transmembrane domain to 
the extracellular space131,132. A similar topological transition is observed in the case of 
phenylalanine permease (PheP) upon PE reduction. In this instance, PheP is able to undergo 
complete inversion of its N-terminal first helical hairpin135. With evidence that such domain 
transitions have been observed for other membrane proteins, it may be possible that NgBR 
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experiences a similar change. Stimulated internalization of NgBR’s transmembrane domain with 
additional N-terminal extracellular residues could result in stabilization of NgBR’s cytosolic 
domain. This may also lend explanation to why NgBR shares sequence identity to UPPs in residues 
other than its cytosolic region. Future experimental approaches including alteration of cellular 
membrane lipid content or ligand induced receptor stimulation, could be used to confirm if NgBR 
is able to exist in such a topological orientation. Altogether, our study opens the way for additional 
exploration into the structural properties of the nogo-b receptor and lends insight into a potential 
molecular basis of how it facilitates farnesylated Ras recruitment and promotes Ras activation.  
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CHAPTER 6 PROTEIN CRYSTALLIZATION: ELUDING THE BOTTLENECK OF X-
RAY CRYSTALLOGRAPHY 
 
Abstract 
 To date, X-ray crystallography remains the gold standard for the determination of 
macromolecular structure and protein substrate interactions. However, the unpredictability of 
obtaining a protein crystal remains the limiting factor and continues to be the bottleneck in 
determining protein structures. A vast amount of research has been conducted in order to 
circumvent this issue with limited success. No single method has proven to guarantee the 
crystallization of all proteins. However, techniques using antibody fragments, lipids, carrier 
proteins, and even mutagenesis of crystal contacts have been implemented to increase the odds of 
obtaining a crystal with adequate diffraction. In addition, we review a new technique using the 
scaffolding ability of PDZ domains to facilitate nucleation and crystal lattice formation. Although 
in its infancy, such technology may be a valuable asset and another method in the crystallography 
toolbox to further the chances of crystallizing problematic proteins.   
A Brief History 
 Protein crystallization was observed more than 170 years ago by Friedrich Ludwig 
Hünefeld with the unintended crystallization of hemoglobin from earth worm blood. This 
accidental finding was described in his book Der Chemismus in der thierischen Organisation 
(Chemical Properties in the Animal Organization) in 1840 136-138. However, it was not until the late 
19th century that scientists began to replicate the crystallization of proteins. Early protein 
crystallization attempts aimed for purification of proteins. Scientists such as Funke in 1851 
purified hemoglobin from red blood cells by dilution of red blood cells with solvents followed by 
slow evaporation to produce hemoglobin crystals 137-139. Sequentially, botanists such as Ritthausen 
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and Osborn implemented similar techniques in the 1880s through the 1890s to purify a series of 
plant seed proteins 137,138,140,141. What was not realized at the time is that this accidental discovery 
would lend far more than the ability to isolate proteins from a sample but would become the 
foundation for the elucidation of high-resolution protein structure. 
 The investigation of molecular crystal structure dates as far back as 1611 when Johannes 
Kepler hypothesized the hexagonal crystal packing of snow in his work Strena seu de Nive 
Sexangula (A New Year's Gift of Hexagonal Snow) 142. However, it was not until the X-ray was 
discovered by Wilhelm Röntgen in 1895 that would make it possible to validate any proposed 
crystal models. In 1912, Max von Laue discovered the diffraction of X-rays by crystals. During 
the period of 1912-1913 William Laurence Bragg developed Braggs Law which describes the 
angles for coherent and incoherent scattering from a crystal lattice 143. It was soon after that Bragg 
reported the first X-ray crystal structure of sodium chloride.   
 With X-ray diffraction in its infancy, the initial pioneers of protein crystallography focused 
on highly abundant proteins that could be produced and purified easily. The first protein structure 
to be solved was that of myoglobin from the sperm whale in 1958 followed by lysozyme from 
chicken egg whites in 1965 144,145. However, as the field progressed, scientists began to direct their 
efforts to objective-oriented projects involving proteins with different molecular weights and from 
different sources. It was then realized that the bottleneck of protein structure determination is the 
production of protein crystals suitable for X-ray diffraction.   
The Premise of Protein Crystallization 
 Protein crystallization today is achieved by the same basic principle as was discovered over 
170 years ago. Supersaturation of a protein in solution is the basis behind the crystallization. At 
the supersaturated state, the amount of proteins in solution exceed their solubility limit. Under this 
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non-equilibrium state, the proteins are being pushed out of the solution undergoing a first ordered 
phase transition known as nucleation. Supersaturation of a protein in solution can be achieved by 
several different methods. Usually, a chemical known as precipitant is used to reduce protein 
solubility and create the supersaturation state. The phase diagram (Fig. 14A) demonstrates the 
dependence of increasing protein and precipitant concentration on the saturated state. At both low 
protein concentration and precipitant concentration, the protein remains in the stable, 
undersaturated state. As either protein or precipitant concentration is increased in solution, the 
protein can undergo a transition to either the metastable, labile, or precipitation phase 137,138,146. In 
the metastable phase, nuclei may form, which are stable compared to the parent liquid phase and 
metastable compared to the crystalline phase of the protein 147. The labile phase is where both 
nucleation and crystal growth may occur 148. The precipitation phase is where the highest degree 
of supersaturation exists, in which ordered nucleation does not occur and there is no crystal growth. 
Thus, crystallization is dependent on the magnitude and rate at which supersaturation is achieved.  
 There are several methods that can achieve the ideal supersaturation state for nucleation 
and crystal growth. Most methods can be placed into one of three categories: vapor diffusion (VD), 
batch crystallization, or liquid-liquid diffusion 138,148. Vapor diffusion is the most extensively used 
method that includes two different techniques: hanging-drop vapor diffusion (HD-VD) or sitting-
drop vapor diffusion (SD-VD). In both techniques, the protein and precipitant are equilibrated 
against the crystallization reservoir solution separated by an air gap. Their difference is simply as 
each name implies. In the SD-VD method, the protein/precipitant mixture resides in a well sitting 
above the reservoir solution. Whereas in the HD-VD method, the protein/precipitant mixture is 
hanging over the reservoir solution from an inverted glass slide. In each setting, water vapor  
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diffuses from the drop into the reservoir solution slowly concentrating the protein/precipitant 
mixture, promoting supersaturation and ideally nucleation of the protein.  
 Batch crystallization is a method in which both concentrated protein and precipitant are 
mixed together and covered by a layer of paraffin oil 137,138,146,149. This technique can be used for 
very small volumes, often referred to microbatch crystallization with droplets as small as 1µl 137,150. 
In batch crystallization, the crystallization conditions can be finely controlled due to the inability 
Figure 14. Carrier mediated protein crystallization. (A) The phase diagram for protein 
crystallization. (B) Conformational change of MBP upon binding of maltose. Unbound (left), 
bound (middle), and superposition of the unbound and bound forms (right). (C) Crystal lattice 
formation as mediated by antibody fragments. Left, the crystal lattice of KscA K+ channel 
mediated by an Fab fragment (PDB code 1K4C); right, the crystal lattice of COX mediated by 
a recombinant Fv fragment (PDB code 1QLE). 
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of air to penetrate the oil layer. Airborne contamination and other variables are blocked from 
contacting with the sample reducing interference in protein crystallization 137,148. 
Liquid-liquid diffusion (also known as counter diffusion) is a technique in which the protein and 
precipitant are injected on each side of a closed channel and gradually mixed through diffusion 
138,148,151,152. At the beginning of mixing, the two solutions come into contact at their maximum 
concentrations in a reagent chamber, resulting in supersaturation and promoting spontaneous 
nucleation. As the mixing proceeds, the mixture reaches equilibrium and the level of 
supersaturation is decreased, consequently favoring crystal growth. This method can be performed 
in a variety of configurations; for example, microfluidic devices have been developed using 
capillaries and microchips which now allow for in situ X-ray data collection 148,151.  
Screening and Additives 
 In a typical crystallization experiment, thousands of conditions are often tested for a single 
protein in order to acquire a crystal suitable for X-ray diffraction. Variables that may affect 
crystallization include pH, temperature, and precipitant concentration. The pH is typically 
controlled by introducing a buffering agent into the crystallization condition. Buffering agents that 
are commonly used include Tris hydrochloride, HEPES, sodium cacodylate, and sodium acetate. 
Precipitants are among the most variable factors and can be divided into four different categories 
based on their properties: salts, organic solvents, long chain polymers, and low-molecular-weight 
polymers and nonvolatile organic compounds 138. Common salts include ammonium sulfate or 
sodium chloride whereas common organic solvents include ethanol and isopropanol. The 
polyethylene glycol family (PEG) such as PEG3350 is representative of the third category whereas 
PEG1000 or less along with compounds such as methylpentanediol (MPD) are representative of 
the latter 138. 
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 Additives can be classified as any foreign molecule introduced into the crystallization 
condition other than the aforementioned components. The purpose of adding additives is to 
facilitate or enhance crystal formation or growth. Examples may include small molecules, 
detergents, metal ions, or other various compounds. Additives do not necessarily promote 
supersaturation of the protein in solution but are intended to contribute to protein solubility or 
structural rigidity. These compounds can often perturb sample to sample and solvent to solvent 
interactions influencing the behavior of protein crystallization. There are several reports in which 
inclusion of additives resulted in improvement of both crystal size and quality 153-155. However, 
screening numerous random molecules is tedious, and success is often limited. Thus, a more 
rational approach is the introduction of natural additives or compounds already found to interact 
with the protein of interest. These types of additives might include cofactors or ligands required 
for the biological activity of the protein. Such molecules not only facilitate successful 
crystallization but also provide functional insight into the protein by revealing the substrate or 
cofactor binding site 156-158. 
Construct Optimization 
 Although supersaturation is the premise behind protein nucleation and crystallization, the 
protein itself can be a critical variable for the formation of a crystal and subsequent growth. It has 
been argued that the protein, rather than the crystallization condition, may be the most important 
variable in the crystallization process. Solubility and monodispersion of the protein is often 
necessary in successful crystallization experiments. Non-specific aggregation by hydrophobic 
amino acids or flexible protein regions can interfere with directional nucleation and overall crystal 
lattice formation. Therefore, protein construct optimization is often implemented in protein 
crystallography. 
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 During the molecular biology boom of the 1980s and 1990s, proteins that had been 
previously understudied due to their low abundance in the cell could now be cloned, expressed, 
and purified in milligram quantities using bacterial expression systems 137,138. However, the 
technology of molecular cloning would not only pave the way for the study of previously 
unobtainable proteins, but also would allow for manipulation of protein constructs to enhance X-
ray crystallographic studies. Standard polymerase chain reaction (PCR) and recombinant DNA 
technology now allow for the deletion of protein regions that may interfere with crystallization. It 
is common practice in construct development for protein structural analysis to remove flexible 
amino acid sequences. These regions can be identified by a variety of techniques such as limited 
proteolytic cleavage followed by fragment analysis, orthological structure comparison, and 
multiple sequence alignment 159-161. Removal of the flexible regions can reduce conformational 
heterogeneity of the protein and enhance ordered formation of the crystal lattice.    
Surface Residue Modification 
 Besides removal of problematic amino acid sequences from the protein, mutagenesis of 
surface residues may also be implemented to enhance the formation of crystal contacts. One of the 
first successful examples of this strategy was that of human ferritin by Lawson in 1991 in which 
some surface residues were mutated to promote the crystal contacts analogous to the structure of 
the rat isoform 162,163. Subsequent studies by other groups such as McElroy in 1992 with 
thymidylate synthase, Zhang in 1995 with T4 lysozyme, and Zhang in 1997 with leptin showed 
that mutagenesis of surface residues can greatly impact the formation of the crystal lattice 164-166.  
 Chemical modification of surface residues can also facilitate the formation of crystal 
contacts by reducing surface entropy of the protein. The most common approach has been the 
reductive methylation of primary amine groups by dimethylamine-borane in the presence of 
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formaldehyde 167. Residues that are subject to such methylation include exposed lysine or arginine 
side chains and the N-terminal primary amine. This strategy offers some advantages over 
mutagenesis by eliminating the time-consuming process of protein production. Additionally, 
methylation is performed on the intact protein which prevents mutagenesis-induced improper 
folding of the nascent polypeptide 167,168. Furthermore, only residues exposed on the surface of the 
protein will be modified, and those buried in the core or residues responsible for strong protein-
protein interfaces are not affected. However, this method of non-specific surface modification may 
eliminate residues critical for substrate binding or other biologically relevant interactions.  
Fusion Tags  
 Unfortunately, even with direct construct optimization and surface modification of the 
target protein, crystallization success is no guarantee. Optimized constructs may still experience 
solubility or aggregation issues due to the improper folding of the target protein with bacterial 
expression systems. To circumvent these issues, molecular cloning strategies are often used to 
attach a solubility tag to the target protein to promote protein folding and stability. This is often 
accomplished by cloning the target protein into a vector that contains a protein tag which is known 
to fold well and exhibit substantial expression and solubility. The most common solubility tags 
used in crystallography experiments include Small Ubiquitin-like Modifier (SUMO), Glutathione 
S-transferase (GST), Thioredoxin (TRX), avidin/streptavidin tags, and Maltose Binding Protein 
(MBP) 160. Classically, once purified, these fusion tags are removed prior to crystallization using 
an engineered protease site in the linker region between the target protein and tag. In a sequential 
purification step, the tag and protease are separated from the target protein yielding the highly pure 
protein suitable for crystallization.  
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 Incorporation of these large solubility tags has been shown to provide substantial benefits 
especially in bacterial expression systems. It has been estimated that nearly 50% of all 
overexpressed prokaryotic proteins have solubility issues using only a hexahistidine tag (His-tag) 
expression system 160,169,170. Recombinant proteins of eukaryotic origin with a His-tag suffer even 
higher solubility issues 160,171-173. Approaches that are often explored to resolve such issues include 
altering expression conditions such as temperature and induction strategy, and exploring 
alternative bacterial expression strains or eukaryotic expression systems 160,169. However, the 
behavior of individual proteins can vary substantially, so that it is highly advantageous that a more 
universal strategy is implemented. Thus, the solubility tag approach has become widely adopted 
due to its noted success in protein structure elucidation. 
Carrier Mediated Crystallography 
 As previously explained, large protein fusion tags are commonly used in structural biology 
for solubility enhancement and promoting proper folding of the target protein. It is common 
practice to remove these tags prior to crystal screening. This is because: (1) tagged proteins are 
less likely to form well-ordered diffracting crystals due to conformational heterogeneity resulting 
from the linker region; and (2) addition of a large fusion tag lends the possibility that the native 
structure of the target protein is changed or physiologically relevant interactions are altered. 
However, because the tags are often responsible for enhancing solubility and structural integrity, 
removal of them from the target protein can result in unwanted complications 160. Common 
problems from tag removal include precipitation of the target protein and insufficient cleavage, 
both of which can result in reduced protein yield or poor quality of proteins. The alternative to 
such issues is to leave the protein tag attached for crystallization trials 160. Although previously 
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thought to be undesirable, this practice, known as carrier mediated crystallography, is now being 
used to facilitate crystallization of proteins that have proven difficult to crystallize.  
 The concept of carrier mediated crystallography is that by leaving on the fusion tag, the tag 
not only promotes solubility of the target protein but also facilitates nucleation and crystal lattice 
formation by its mediated crystal contacts. This sequentially promotes the incorporation of the 
target protein into the crystal lattice which may not have been possible without the tag. An 
additional benefit of this technique is that the phase problem in X-ray crystallography can be easily 
solved by the molecular replacement method, since most commonly used fusion tags have 
previously solved structures. The structures of fusion tags also allow easy implementation of 
surface entropy reduction to further increase the chances of crystallization success.  
Maltose Binding Protein 
 The first protein structure reported using a fusion tag approach was reported by Center in 
1998 in which two fragments from the ectodomain of human T cell leukemia virus type 1 (HTLV-
1) were crystallized with Maltose Binding Protein (MBP) as the tag 174. Since then, it was described 
by Waugh in 2015 that over 100 crystal structures using MBP as fusion tag have been solved 175. 
MBP is a 42.5kD E. coli protein responsible for the uptake of maltodextrin and promoting its 
catabolism. MBP exists as a monomer in solution and is divided into two distinct globular domains 
connected by three short polypeptide segments. The two globular domains are separated by a deep 
pocket that is responsible for the binding of its substrate maltose or other maltodextrins 176,177. 
MBP can undergo a significant conformational change upon binding to its substrates (Fig. 14B). 
The substrate bound form displays a closed substrate binding pocket and is related to the substrate 
unbound form by a rigid motion of the two domains around the linking polypeptide hinge (Fig. 
14B). The two MBP conformations can give rise to different crystal contacts. Thus, crystallization 
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of MBP fusion proteins is often screened with or without the addition of maltose in order to 
promote monodispersion of MBP’s bound and unbound conformations. This was shown to be 
critical in at least one structure, (PDB code: 3WAI), in which only the ligand free form could be 
crystallized 175,178. In other structures, different crystal forms were observed between the ligand 
bound and unbound forms 175,179.  
 The MBP conformational state is not the only factor that affects MBP mediated 
crystallization. The linker region between MBP and the target protein is also an important variable. 
Eleven MBP fusion structures as noted by Waugh exhibit relatively long linkers designed for 
proteolytic cleavage 175. This suggests that crystallization with the MBP tag in these cases was a 
fall back approach when crystallization attempts of the cleaved protein failed. There is also a 
prevalent consensus of short linkers including N, NS, HM, GS, GSS, AMD, GSSGSS, and NSSS 
175. The linker NSSS is one of the common linkers deposited in the Protein Data Bank and is 
characteristic of the expression vector pMAL-c2 175,180. This linker is created by PCR amplification 
of the target protein sequence with introduction of an in-frame SacI restriction site at the N-
terminus of the protein. However, the most common linker for MBP fusion constructs is that of 
NAAA which is the result of a three point mutations at the MBP C-terminus. These point mutations 
can be traced back to the crystal structure of HLTV-1 gp21 ectodomain fused to MBP 175,181. It 
was anticipated that gp21 would exist as a homotrimer and thus three charged residues near the C-
terminus of MBP were changed to alanine to avoid electrostatic repulsion. These three alanine 
residues code for a NotI restriction site which allows for the in-frame ligation of the target protein 
into the vector 175. The asparagine that proceeds the three alanine residues is a cloning artifact 
introduced from the pMAL-c2 vector. Although there is no definitive answer to whether this linker 
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more likely facilitate MBP mediated crystallization, the predominance of solved structures with 
this linker sequence suggests a good starting point in pursuing MBP carrier crystallization.  
 To further the chances of obtaining a diffracting quality crystal, surface entropy reduction 
can be implemented together with the MBP carrier technique. In 2010, Moon describes a tandem 
fixed arm MBP/surface entropy reduction mutation system, in which both the linker region and 
MBP loop regions are optimized. Custom short linkers were designed to promote a “fixed arm” 
where the conformational flexibility of the linker would be minimized but not interfere with the 
structure of MBP or the protein itself 180. Surface entropy reduction mutations were then introduced 
on the solvent exposed loop regions of MBP. Using this strategy, Moon was able to solve three 
previously unobtainable protein structures including 2-O-sulfotransferase (2OST) from Gallus 
gallus, receptor for activated C-kinase 1 (RACK1) from Arabidopsis thaliana, and Derp7 from 
Dermatophagoides pteronyssinus. Structural analysis showed that some of these surface entropy 
reduction mutations promoted crystal formation likely by reducing electrostatic repulsion in crystal 
contacts 180. 
 One major concern with the MBP mediated crystallization is potential interference of MBP 
with the native conformation of the target protein. Waugh in 2016 addressed this issue by 
investigation of 24 proteins with and without MBP as a fusion partner. Following analysis, it was 
found that the average r.m.s.d (root-mean-square-deviation) for the fused and non-fused structures 
averaged approximately 1 Å suggesting that MBP fusion caused little to no structural change 175. 
Altogether, this suggests that the MBP mediated crystallization is a viable technique that can 
enhance the probability of crystallization success without influencing the native structure of the 
protein target. 
Crystal Structures with Carriers other than MBP 
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 Although the majority of crystal structures deposited in the PDB using the carrier approach 
utilize MBP as the fusion partner, a number of other structures exist using alternative protein tags. 
As described by Smyth in 2003, crystallization of GST fusion proteins have been reported for the 
DNA-binding domain of Drosophila DNA replication-related-element-binding factor and for 
mouse estrogen receptor hormone binding domain 160,182,183. Carter and Schmidt in 2011 and 2012 
revealed the crystal structures of the dynein motor domain of Saccharomyces cerevisiae with GST 
fusion 184,185. In addition to GST, yeast SUMO was also reported as a fusion partner in 
crystallization. The SUMO tag is widely implemented in protein purification because of its high 
solubility; however, it is typically cleaved off prior to crystallization186-188. Regardless, at least nine 
unique SUMO fusion protein structures have been deposited in the PDB including C-terminal 
domain of Ebola virus VP30, thymidylate synthase, alpha-keto acid dehydrogenase phosphatase, 
and peptidyl-prolyl cis-trans isomerase. However, despite a limited amount of research on either 
GST or SUMO fusion, both tags may serve as a viable alternative for carrier mediated 
crystallography. 
Antibodies as a Carrier Mediated Approach 
 An alternative carrier approach to the fusion protein is the use of antibody fragments in the 
facilitation of crystal formation. In this technique, crystal contacts are mediated between antibodies 
specifically bound to the protein of interest. One of the first uses of this technique was for the 
crystallization of the HIV capsid protein p24 where traditional crystallization methods were 
unsuccessful 189,190. It was only after screening with antibody fragments that crystals suitable for 
X-ray diffraction were obtained. Antibodies can be divided into two regions that include the Fab 
region and Fc regions. The Fab region contains the sites that can bind to antigens, whereas the Fc 
region allows for the generation of an immune response 191. The Fab region is composed of one 
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variable domain and one constant domain from each the light chain and heavy chain of the antibody 
192. The variable domains are collectively known as the Fv region and is the most important region 
for binding antigens, constituting specificity and antigen discrimination.  
 When using antibodies as a carrier in crystallography, the most important part is selection 
and preparation of homogenous Fab fragments specific for the protein target. The use of entire 
antibodies can hinder crystal lattice formation due to the flexibility between the Fab and Fc 
193,194. 
Thus, the use of Fab fragments is the most common approach in this technique. One approach that 
can be used to isolate the Fab fragments is to subject the antibodies to papain digestion which 
cleaves the flexible domain between the Fab and Fc regions 
189. The resulting Fab fragments are then 
purified by ion exchange chromatography to remove the Fc region. Although cleaved Fab fragments 
are relatively easy to obtain, care must be taken in the purification procedure to ensure 
homogeneity of the fragments. The more definitive approach to generating identical Fab or even Fv 
regions is the use of recombinant methods that can ensure homogenous fragments for 
crystallization 193.  
 Once purified, the fragments are then mixed with the respective protein target and standard 
crystallization procedures are implemented. As shown by Hunte and Michel in 2002, the crystal 
contacts in the KcsA K+ channel crystal are entirely mediated by the Fab fragments, virtually 
suspending the target protein within the crystal lattice (Fig. 14C) 193,195. The same was noted for 
the crystallization of cytochrome c oxidase (COX) where all crystal contacts are mediated by the 
bound Fv fragments (Fig. 14C) 
193,196. These observations suggest that the antibody fragments can 
provide substantial benefits in the mediation of protein crystallization. The high affinity of the 
antibody for its target eliminates the need for a linker as with the fusion method and reduces the 
conformational flexibility of the protein molecule. Additionally, as observed in the crystal 
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structures of KscA and COX, crystal lattice formation can be achieved purely by the antibody 
fragments eliminating the need for the manipulation of crystal contacts from the target molecule. 
However, even with recombinant methodologies, this approach can be very costly and labor 
intensive making this strategy often one of last resorts in protein crystallography.   
Nanotechnology in Protein Crystallography 
 Regardless of the method used to facilitate crystallization of a protein, crystal formation is 
limited by the laws of chemistry and the insurmountable variables involved in macromolecular 
interactions. When simplified, the three key components to crystallization success is nucleation, 
conformational stability, and ordered protein-protein contacts. With every strategy, there are 
strengths and limitations. However, technological advancement continues to open alternate 
pathways to overcome this barrier. Nanotechnology and the use of nanoparticles has been 
extensively explored in recent years due to its wide range of practical application in physics, optics, 
electronics, and even medicine. Nanoparticles can be defined as an ordered cluster of atoms, 
typically inorganic materials, that have at least one dimension between 1 and 10 nanometers. They 
tend to be highly reactive and have been used for conjugation to a variety of molecules with 
applications in protein crystallography. 
 An example of such technology was described by Ko in 2016 in which nanoparticles served 
as an inducing reagent in protein nucleation and crystal growth 197. Ko demonstrated that formation 
of lysozyme nucleation cores can be accelerated by decoration of gold nanoparticles with -COOH 
and Ni2+ ions. The interactions between lysozyme and the immobilized -COOH and Ni
2+ions can 
readily conjugate lysozyme to the nanoparticles creating the nucleation core 197. Manipulation of 
nanoparticle size and shape increased the number of successful crystallization conditions by 24%. 
Chen in 2017 described another approach for nucleation induction using nanodiamond (ND) 
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carbon based particles. Like the gold particles described by Ko, NDs were modified with various 
oxygen containing groups including -COOH, -COH, and -C=O for protein conjugation 198. Chen 
reported that the nanoparticles were able to increase crystallization efficiency of several proteins 
including lysozyme, ribonuclease A, proteinase K, and catalase 198. NDs were also able to 
effectively induce crystallization of lysozyme at concentrations as low as 5 mg/mL. This finding 
indicates that the nanoparticles can facilitate the crystallization of proteins at low concentration or 
at ultra-low supersaturation.  
 In addition to the nanoparticles, several other technological innovations are being explored 
as potential facilitators of crystallization. Crystallization mediated by porous materials such as 
silicon has been examined. Microfluidic devices have also been developed to increase protein 
crystallization efficiency 199,200. Crystallization of membrane proteins using lipidic bicelles have 
been reported with variable success 201-203. Although no single technique has been successful for 
the crystallization of all proteins, each method can be implemented as a potential option for 
successful protein crystallization.        
PDZ Domains in Nucleation and Crystal Facilitation 
 With efforts to expand the crystallization toolbox, our laboratory has recently begun to 
develop additional approaches to facilitate protein nucleation and crystal formation. One of our 
approaches was designed to simulate biological protein scaffolding in which protein-protein 
interaction known to mediate protein complex formation was exploited as a carrier for 
crystallization. Because the essence of nucleation is ordered protein contacts which results in the 
formation of a crystal lattice, the use of scaffolding proteins as a carrier may increase the chance 
of well-ordered interactions. The following will describe the potential of using the scaffolding 
properties of PDZ domains in facilitation of crystal lattice formation. 
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 PDZ domains are composed of 80-90 amino acids that play critical roles in protein 
scaffolding and complex assembly at the cellular membrane. The acronym PDZ is derived from 
the first three proteins originally found to contain this domain. These three proteins are known as 
Postsynaptic density protein 95kD (PSD95), Drosophila disc large tumor suppressor (Dig1), and 
Zonula occludens-1 protein (ZO-1) 22,45. PDZ domains bind to their targets by recognizing specific 
short C-terminal amino acid motifs of their targets. This structurally conserved interaction 
promotes scaffolding of protein complexes and is important for the assembly of signaling 
complexes, protein trafficking, and the recycling of cell receptors 23. PDZ domains can be 
classified as either class I or class II based on their substrate specificity. Class I PDZ domains 
recognize the C-terminal peptide consensus sequence (S/T)X(V/I/L) (X denoting any amino acid) 
and class II recognizes (F/Y)X(F/V/A) 52,80. All PDZ domains share an evolutionary conserved  
fold consisting of six β-strands (β1-β6) and two α-helical segments (αA and αB). A similar peptide 
recognition mode is shared among all PDZ domains with the target peptide inserted between the 
strand β2 and helix αB 1,2,43,45,52,80,116. Many PDZ proteins increase their scaffolding capability 
through dimerization and promote formation of large macromolecular complexes 43,54-56.  
 Numerous PDZ-substrate complexes have been crystallized. One unique and effective 
strategy in these crystallizations is the use of a chimeric protein construct, i.e. the peptide ligand 
attached to the C-terminus of the PDZ molecule (Figure 15A) 1,2,43,116. In the crystal, the chimeric 
protein displays a polymeric arrangement with the C-terminal ligand sequence bound to a 
neighboring PDZ, leading to the formation of a linear filament throughout the crystal (Fig. 15B). 
This repeated “pocket and tail” interaction appears to facilitate directional nucleation contributing 
to crystal contact formation between adjacent PDZ molecules. This strategy has proven essential  
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for the crystallization of NHERF1 PDZ1 which was not able to be crystallized without the peptide 
substrate fusion 2. 
 Inspired by this effective chimeric protein approach, we designed a dual fusion construct 
with the target protein sandwiched by a PDZ domain and its respective peptide ligand (Fig. 15A). 
The goal of building this construct is to explore the potential of specific PDZ-ligand interaction in 
promoting the crystallization of other proteins. Since the crystallization of PDZ domains is 
facilitated by the attachment of the C-terminal peptide substrate, our concept is that adding a PDZ 
molecule to the N-terminus of the target protein and a specific PDZ substrate peptide to the protein 
C-terminus may facilitate nucleation (Fig. 15C). The N-terminally fused PDZ domain would 
Figure 15. PDZ scaffold mediated protein crystallization. (A) A chimeric PDZ-substrate fusion 
construct (top) and a dual protein fusion construct with a target protein sandwiched by a PDZ 
domain and PDZ substrate peptide (bottom). (B) Crystal contacts mediated by the repeated 
“pocket and tail” interactions in the crystal of NHERF1 PDZ1-CXCR2 fusion protein (PDB 
code 4JL7). (C) Theoretical representation of crystal contact formation in PDZ scaffold 
mediated protein crystallization. (D) Crystals obtained for NHERF1/PDZ1-NgBR-CXCR2 
(top) and NHERF1/PDZ1-SMYD5-CXCR2 (bottom). (E) Expression and solubility 
assessment of NgBR with and without N-terminal PDZ fusion. Lane M, molecular weight 
marker; U, uninduced cell culture; I, induced cell culture; T, total cell lysate; S, supernatant of 
cell lysate. 
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recognize the C-terminally fused peptide substrate from another fusion protein, creating a chain of 
interactions that would facilitate crystal lattice formation. As with antibody mediated 
crystallization, the target protein could be virtually suspended within the crystal lattice reducing 
the necessity for the formation of crystal contacts from the target protein itself. Although in its 
infancy, our laboratory has employed this strategy for two proteins, NgBR (Nogo-B receptor) and 
SMYD5 (SET and MYND domain containing protein 5), for which standard crystallization 
methods have been unsuccessful. Interestingly, small crystals were obtained for both proteins in 
very similar conditions suggesting that the crystallization was mediated by PDZ-ligand interaction 
(Fig. 15D). In addition, PDZ domains are very soluble and stable in solution. Using them as a 
fusion partner could also increase the solubility of the target protein. This was verified in one 
instance when comparing the expression profile of NgBR with and without the N-terminally 
attached NHERF1 PDZ1 domain (Fig. 15E). Thus, our dual fusion protein approach not only 
provides a molecular scaffold for crystallization but also is able to increase protein solubility. 
Furthermore, optimization of this strategy may prove as an additional approach for crystallization 
of problematic proteins. 
Concluding Remarks 
 X-ray crystallography continues to be the leading method for the elucidation of protein 
structure and rational drug design. However, the unpredictability of protein crystallization can 
significantly suppress the rate at which such discoveries are made. Although no crystallization 
method has guaranteed success, numerous strategies have been employed in order to increase the 
probability of which it can occur. Adjustment of crystallization components, modification of the 
protein construct, addition of carrier molecules, or even synthetic materials can be used alone or 
in combination to increase the odds at which the target protein can be crystallized. Additionally, 
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utilization of the natural PDZ scaffolding ability may be implicated as an additional strategy for 
the induction of nucleation as well as facilitating the formation of crystal contacts. Together, all 
the strategies reviewed here are viable approaches which may help evade the bottleneck of 
crystallography and advance the analysis of protein structures. 
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 Protein structural elucidation by means of X-ray crystallography is a powerful approach 
for both insight into a proteins biophysical properties and function. To date X-ray crystallography 
remains the gold standard in high resolution structural determination and serves as the basis for 
rational drug design for the purpose of combating a number of human diseases. Such an approach 
also allows for the exploitation of how various proteins interact with their substrates providing a 
molecular basis for their physiological function. In this dissertation, using X-ray crystallographic 
analysis along with other biophysical characterization methods, we seek to understand the 
mechanistic foundation for which scaffolding proteins such as NHERF1 and NHERF2 interact 
with their substrates in which leads to a wide variety of critical cellular events. Additionally, we 
elucidate the structure and function of a recently identified membrane protein, NgBR, with hopes 
to understand the molecular basis in which it influences the activation of the infamous oncoprotein 
Ras.    
 Protein scaffolding is a term that denotes the coming together of two or more proteins in 
which results in the formation of macromolecular complexes. Such events are known to regulate 
104 
 
 
 
several cellular processes including membrane protein recycling, protein stabilization, cell to cell 
adhesion, and regulation of signaling pathways. There are several families of scaffolding proteins 
with one of the most known to be the PDZ domain containing family. Two proteins within this 
family, NHERF1 and NHERF2, contain two PDZ domains in which are responsible for a variety 
of signaling events. The second PDZ domain of NHERF1 has been shown to complex with 
chemokine receptor CXCR2 and mediate the formation of the CXCR2-NHERF1-PLCβ2 complex. 
This complex formation has been shown to be influential in chemokine induced neutrophil 
migration and infiltration in regions of inflammation leading to the exacerbation of a variety of 
inflammatory diseases. Additionally, the first PDZ domain of NHERF2 has been shown to mediate 
the scaffolding of the CFTR-NHERF2-LAP2 complex which has been shown to inhibit CFTR 
activity by the LPA2 mediated inhibition of adenylate cyclase. Furthermore, disruption of this 
complex has been shown to be enough to augment CFTR activity in vivo. And thus, the 
determining the molecular basis by means both NHERF1 and NHERF2 scaffolding with its 
respective targets could lead to therapeutic targeting in a variety of human diseases. In this 
dissertation, we solved the co-crystal complexes between both NHERF1 PDZ2 with the C-terminal 
peptide of CXCR2 in addition to solving the co- crystal complex between NHERF2 PDZ1 with 
the C-terminal LPA2 peptide. Both structures reveal an expected mode of type 1 PDZ substrate 
recognition with various ligand specific interactions. However, both structures also reveal 
unexpected findings which may unveil additional therapeutic strategies other than targeting the 
PDZ substrate binding site.  
 The Nogo-B receptor is a recently identified type one transmembrane receptor with little 
known function besides its role in binding Nogo-B and promoting angiogenesis by chemotaxis in 
vivo. However, its most recently identified role is that of binding and facilitating the oncoprotein 
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Ras to the plasma membrane for activation. No X-ray crystallographic structure currently exists 
for NgBR but previous studies have confirmed to be composed of three primary domains including 
a cytosolic and extracellular domain with one transmembrane region. However, successive data 
have suggested that NgBR may exist in more than one topological orientation. Because previous 
attempts to crystallize NgBR have failed due to solubility issues and since it has been observed to 
possess various topological orientations, we chose to exploit NgBR’s structural properties using a 
complimentary approach to X-ray crystallography known as small angle x-ray scattering (SAXS). 
By incorporation of residues in our expression construct in which share sequence identity to the 
cis-IPTase UPPs, we are able to achieve good solubility and purification of our NgBR construct. 
Additionally, SAXS analysis reveals that our NgBR construct exists as a globular macromolecule 
in solution which may pave the way for future high resolution structural studies.  
 Altogether, X-ray crystallography is a powerful technique for the determination of protein 
structure. The only bottleneck of this approach is the obtainment of a protein crystal. The final 
chapter in this thesis overviews well known and leading techniques in the evasion of this rate 
limiting step in the pursuit of solving molecular structure. And although there is still no one method 
for guaranteeing the formation of a protein crystal, X-ray crystallography continues to unveil new 
structural information and potential therapeutic targets which can be implicated in the 
advancement of molecular medicine.       
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